

RANDOX

RANDOX INTERNATIONAL
QUALITY ASSESSMENT SCHEME



RIQAS

RANDOX

QUALITY CONTROL

RIQAS

THE LARGEST INTERNATIONAL EQA SCHEME
WITH OVER 76,000 LAB PARTICIPANTS



| | |
|-----------|---------------------------------|
| 01 | BENEFITS |
| 02 | EQA |
| 03 | RIQAS REPORTS |
| 04 | WEB-BASED DATA TRANSFER |
| 05 | PARTICIPATION IN RIQAS |
| 06 | STANDARD REPORT |
| 14 | END-OF-CYCLE REPORT |
| 20 | MULTI-INSTRUMENT REPORT |
| 21 | URINE TOXICOLOGY REPORT |
| 24 | URINALYSIS REPORT |
| 25 | SEROLOGY REPORT |
| 28 | SERUM INDICES REPORT |
| 33 | BACTERIAL IDENTIFICATION REPORT |
| 39 | MONITORING EQA PERFORMANCE |
| 42 | RIQAS PROGRAMMES |
| 47 | PARAMETER INDEX |
| 59 | RANDOX QC PORTFOLIO |
| 60 | CONTACT US |

BENEFITS

Delivering a comprehensive yet cost effective EQA solution, RIQAS will help meet regulatory requirements and increase confidence in test system accuracy.



Large Database of Users

- A high level of participation means peer group numbers are maximised whilst ensuring availability of data for a wide range of instruments and methods.



User-friendly Reports

- Simple, one page per parameter format, enables at-a-glance performance assessment, saving valuable laboratory time.
- Complimentary multi-instrument and interlaboratory reports allow comparative performance assessment of all laboratory systems and multiple connected laboratories.
- End-of-Cycle reports, summarising performance compared to the previous cycle, allows you to identify improvements in quality over time.



Cost Effective

- Our extensive range of multi-analyte programmes will reduce the number of individual programmes required to cover your test menu, saving both time and money.
- Reduced parameter options for selected programmes offer greater flexibility, ensuring suitability for laboratories of all sizes and budgets.
- Register up to five instruments per programme (volume permitting) at no extra cost for comparative performance assessment.



Frequency

- Frequent reporting allows early identification of system errors and implementation of any necessary corrective actions with minimum disruption to the lab.
- With a turnaround of less than 72 hours for most reports, corrective action can be implemented earlier, potentially reducing costly errors with patient results.



High Quality Samples

- Samples spanning clinically relevant levels allow identification of concentration related biases, helping to ensure accurate instrument performance.
- Human samples free from interfering preservatives increase confidence that EQA performance mirrors the performance of patient samples.
- Reference method values are provided in the Clinical Chemistry programme for selected parameters and lots, while for the Immunosuppressant programme they are provided for all parameters and lots.



Highly Accredited

- Programmes accepted by National and International accreditation bodies worldwide.
- Participant certificates provide evidence of participation in a reputable EQA scheme.

RIQAS is the largest international EQA scheme in the world. It is used by more than 76,000 laboratory participants in 139 countries. 35 programmes are currently available.

RIQAS Programmes

- Ammonia/Ethanol
- Anti-Müllerian Hormone (AMH)
- Anti-TSH Receptor
- Blood Gas
- BNP
- Cardiac
- Cardiac Plus
- Cerebrospinal Fluid (CSF)
- Clinical Chemistry
- Coagulation
- CO-Oximetry
- CYFRA 21-1
- Cytokines
- ESR
- Glycated Haemoglobin (HbA1c)
- Haematology
- Human Urine
- Immunoassay
- Immunoassay Speciality 1
- Immunoassay Speciality 2
- Immunosuppressant Drugs
- Lipids
- Maternal Screening
- Microbiology (Bacterial Identification)
- Neonatal Bilirubin
- Serology Epstein Barr Virus (EBV)
- Serology (HIV/Hepatitis)
- Serology (Syphilis)
- Serology (ToRCH)
- Serum Indices
- Specific Proteins
- Sweat Testing
- Therapeutic Drugs
- Urinalysis
- Urine Toxicology

Accreditation

- RIQAS provides certificates as proof of EQA participation and performance for laboratory accreditation purposes.
- RIQAS is a UKAS accredited Proficiency Testing Provider, No. 0010, and is accredited to ISO/IEC 17043:2010, 'Conformity Assessment- General Requirements for Proficiency Testing'.
- Accreditation to ISO/IEC 17043:2010 highlights the superior quality and excellence of RIQAS.

UK Performance Surveillance

- Recognised by the Quality Assurance in Pathology Committee (QAPC).
- Recognised by various National Quality Assurance Advisory Panels (NQAAP).

Independent Advisory Panel

RIQAS participants have access to an independent advisory panel consisting of scientific and clinical experts. This ensures professional and ethical conduct of the scheme and participant confidentiality.


**RIQAS support staff are on hand to offer
 advice and troubleshoot technical queries.**

RIQAS REPORTS

RIQAS reports are presented in a user-friendly, one page per parameter format. This allows easy interpretation of your analytical performance.

RIQAS Reports

- Statistical breakdown by all methods, your method and, where applicable, your instrument, including running means for the last 10 samples.
- Compare your instrument group, method group and all methods using the histogram.
- Identify trends, biases and precision problems using the visual charts.
- The Target Score chart uniquely grades your performance in a moving window over the last 20 samples, including the previous cycle.
- At-a-glance summary page for all parameters in the programme.
- Compare your result with statistically robust consensus means.
- Identify acceptable and poor performance using fit-for-purpose performance indicators:
 - SDI
 - %Deviation
 - Target Score



Summary CSV Files

It is possible to receive an additional summary of your report statistics, acceptable limits and performance indicators as a .csv file for every sample (*available for quantitative reports only*).

Multi-Instrument Reports

Laboratories can register up to five instruments at no extra cost. Individual reports for each instrument plus a unique multi-instrument report are provided. The multi-instrument report plots the performance of each individual instrument on a single, colour coded Levey-Jennings chart, ensuring instant identification of any differences in instrument performance. Additional sample packs may be ordered as required if volume supplied is insufficient for the registered instruments.




Laboratory Group Reports

The group reporting facility enables laboratory groups or chains to monitor the performance of satellite sites. Each affiliated laboratory will receive their individual reports with the group supervisor also receiving a summary report comparing each laboratory in the network.

WEB-BASED DATA TRANSFER

RIQAS.Net offers easy, direct access for the submission of results and retrieval of reports direct from the RIQAS host server.

- Available in multiple languages.
- Confidentiality and security is maintained through the use of password protected access.
- Submit current, corrected and future results (normal policies apply), directly into the RIQAS database. Receipt of results is confirmed by e-mail.
- Multi-lingual registration identifier provides simple identification of multiple registrations.
- Additions and changes to assay details can be made quickly and easily online.
- Requests for new method, instrument and reagent codes can be made online.
- Reports are emailed in PDF format as soon as they are prepared.
- Reports for the previous two cycles can be downloaded from the website.
- View, print, store or distribute reports as you wish.
- Update your laboratory's certificate of participation details in multiple languages.
- All that is required is web access, Adobe Reader (for viewing reports) and a valid password to access the system.
- No additional software required.




PARTICIPATION IN RIQAS

Participation in RIQAS follows these simple steps:



Performance data is presented in a one page format with up to seven sub-reports.



- 1 **Text Section Chart:** Statistics for all methods, your method and instrument group (programme specific).
- 2 **Histogram Chart:** Method and instrument comparison.
- 3 **Multi-Method Stat Section Chart:** Enables assessment of the performance of each method.
- 4 **Levey-Jennings Chart:** Details features of your laboratory's performance.
- 5 **Target Score Chart:** This unique chart provides a numerical index of performance, allowing at-a-glance assessment.
- 6 **%Deviation by Sample Chart:** Helps to identify trends and shifts in performance.
- 7 **%Deviation by Concentration Chart:** Rapid assessment of concentration related biases.

TEXT SECTION

The text section summarises the statistical information for each parameter.

| Glucose, mg/dl | | 2 | 3 | 4 | 5 | 6 | 7 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|------------------------------------|---------|-------------|---------|----------------|------|------|--|--|--|-------|------|----|---|---------------------|---------|----|-----|----|--|--|--|------|-----|----|----|-----------------|---------|------|-----|----|--|--|--|--------|-----|----|--|--|---|-----|----|--|-------|----|
| | | N | Mean | CV% | U _m | SDPA | Exc. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <input type="checkbox"/> | All Methods | 6598 | 108.157 | 3.9 | 0.06 | 5.33 | 621 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <input checked="" type="checkbox"/> | Hexokinase | 3524 | 108.234 | 2.9 | 0.07 | 5.33 | 285 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <input checked="" type="checkbox"/> | Roche Cobas c501/502 e601/602 e801 | 677 | 107.618 | 2.2 | 0.12 | 5.30 | 48 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <table border="1"> <tr> <td>▲</td> <td>Your Result</td> <td>110.300</td> <td>SDI</td> <td>0.51</td> <td>9</td> </tr> <tr> <td></td> <td></td> <td></td> <td>RMSDI</td> <td>0.40</td> <td>10</td> </tr> <tr> <td>■</td> <td>Mean for Comparison</td> <td>107.618</td> <td>TS</td> <td>101</td> <td>11</td> </tr> <tr> <td></td> <td></td> <td></td> <td>RMTS</td> <td>107</td> <td>10</td> </tr> <tr> <td>15</td> <td>Reference Value</td> <td>105.179</td> <td>%DEV</td> <td>2.5</td> <td>12</td> </tr> <tr> <td></td> <td></td> <td></td> <td>RM%DEV</td> <td>2.0</td> <td>10</td> </tr> </table> | | ▲ | Your Result | 110.300 | SDI | 0.51 | 9 | | | | RMSDI | 0.40 | 10 | ■ | Mean for Comparison | 107.618 | TS | 101 | 11 | | | | RMTS | 107 | 10 | 15 | Reference Value | 105.179 | %DEV | 2.5 | 12 | | | | RM%DEV | 2.0 | 10 | <table border="1"> <tr> <td>Acceptable limits derived from Biological Variation</td> <td>N/A</td> <td>13</td> </tr> <tr> <td>Acceptable limits of performance for RIQAS</td> <td>8.10%</td> <td>14</td> </tr> </table> | | Acceptable limits derived from Biological Variation | N/A | 13 | Acceptable limits of performance for RIQAS | 8.10% | 14 |
| ▲ | Your Result | 110.300 | SDI | 0.51 | 9 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | RMSDI | 0.40 | 10 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ■ | Mean for Comparison | 107.618 | TS | 101 | 11 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | RMTS | 107 | 10 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 15 | Reference Value | 105.179 | %DEV | 2.5 | 12 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | RM%DEV | 2.0 | 10 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Acceptable limits derived from Biological Variation | N/A | 13 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Acceptable limits of performance for RIQAS | 8.10% | 14 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Performance statement appears here if performance indicators exceed limits | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

RIQAS performance indicators include SDI, Target Score and %Deviation.

Acceptable performance criteria:

SDI < 2
Target score ≥ 50
%Deviation ≤ defined acceptable limits

- Report is presented in your chosen unit.
- Number of returned results used to generate Mean for Comparison.
- Average value of all laboratories' results.
- Coefficient of Variation.
- Uncertainty associated with the Mean for Comparison.

$$U_m = \frac{1.25 \times SD}{\sqrt{n}}$$
- SDPA = Standard Deviation for Performance Assessment, calculated from the Target Deviation for Performance Assessment (TDPA) and the Mean for Comparison.

$$SDPA = \frac{TDPA \times \text{Mean for Comparison}}{t\text{-value} \times 100}$$

t-value = factor which represents the % of poor performers reflected in the TDPA (t-value ~ 1.645 when ~10% laboratories achieve poor performance), SDPA is combined with U_m, where appropriate.

If U_m > (0.3 x SDPA) then $SDPA_{\text{adjusted}} = \sqrt{(U_m^2 + SDPA^2)}$ and the reported value is suffixed with "a"

If U_m is less than (0.3 x SDPA) then $SDPA_{\text{adjusted}} = SDPA$
- After statistical reduction, some results are excluded from the mean for comparison.
- Ideally this will be your instrument group mean. If N<5 for instrument group, your method group mean is selected as Mean for Comparison.
- Standard Deviation Index = $\frac{\text{Your Result} - \text{Mean for Comparison}}{SDPA_{\text{adjusted}}}$
- Running Mean average of the last 10 performance indicators is used to monitor performance over time and concentration range.
- Target Score - The closer a value is to 120, the better the performance.

$$TS = \log_{10} \left(\frac{3.16 \times TDPA}{|\%Dev|} \right) \times 100$$
- %Deviation from the Mean for Comparison -


$$\%Dev = \frac{\text{Your Result} - \text{Mean for Comparison}}{\text{Mean for Comparison}} \times 100$$

The closer the value is to zero, the better the performance.
- Biological Variation - Not currently available - please review online.
- Performance limit set for this parameter.
- Reference values quoted for information purposes, where applicable.

HISTOGRAM

The Bar Graph is intended as a quick visualisation of how your lab's result compares to the method mean, instrument mean and all method mean.

- All methods
- Your method group
- Your instrument group
(programme specific)



- 1 Total of 1126 laboratories reported values between 106.55 & 108.15.

2 200 laboratories reported values between 101.77 & 103.36 in your method group.

3 RIQAS reports show your unit of measurement.
- 4 Your result is indicated by the black triangle.

5 41 laboratories reported values between 111.35 & 112.94 in your instrument group.


MULTI-METHOD STAT SECTION

This section provides an easy way of assessing the performance of other methods used to analyse the parameter in question.

| Method | N | Mean | CV% | U_m |
|---------------------------------|----------|-------------|------------|----------------------|
| Hexokinase | 3524 | 108.234 | 2.9 | 0.07 |
| Glucose oxidase | 2673 | 108.474 | 5.5 | 0.14 |
| Ortho Vitros MicroSlide Systems | 251 | 105.036 | 2.3 | 0.19 |
| Glucose dehydrogenase | 63 | 107.832 | 3.5 | 0.59 |
| GOD/02-Beckman method | 37 | 106.425 | 2.5 | 0.55 |
| Other Dry Chemistry | 27 | 108.360 | 6.3 | 1.64 |
| Agappe - GOD-PAP | 21 | 109.727 | 3.7 | 1.11 |
| Oxygen electrode | 17 | 106.666 | 1.3 | 0.43 |
| Vitros, DT60/DT60 II | 3 | 105.595 | 3.9 | 2.99 |

LEVEY-JENNINGS CHART

SDIs reflect laboratory performance in relation to fit-for-purpose SDPAs and are useful to monitor performance over time. Acceptable performance is $SDI < 2$.



1 The Mean for Comparison for each sample is indicated at the top of the chart. This allows easy assessment of concentration related bias:

- I: Instrument mean
- M: Method mean
- A: All method mean

2 This line indicates a change in registration details for this parameter.

3 Your SDI (Standard Deviation Index).

4 Sample number.


5 N = No result returned in time for this registration\sample.

6 C = Corrected results will be accepted for non-analytical errors. Corrected results will be accepted up to 4 weeks after the final submission deadline, on application, with evidence of analysis. Late results are only accepted if there has been a Randox error.

R = Incorrect results can be removed retrospectively on request.

TARGET SCORE CHART

The Target Score (TS) allows you to assess your performance at a glance. The TS relates the %Deviation of your result from the Mean to a Target Deviation for Performance Assessment (TDPA). TDPA's are set to encourage participants to achieve and maintain acceptable performance. TDPA's are fit-for-purpose performance criteria which are set taking guidance from ISO/IEC17043, ISO13528 and IUPAC. Target Deviations for Performance Assessment are also used to calculate the Standard Deviation for Performance Assessment (SDPA).



1 This is the upper deviation limit of performance for this parameter. TDPA's are reviewed regularly and deemed fit for purpose by the RIQAS Advisory Panel.


2 High scores ≥ 50 in the lighter shaded area represent acceptable, good or excellent performance.

3 Heavy shading for values 10 to 50 signifies poor performance.

%DEVIATION CHARTS


The %Deviation by sample chart helps to identify trends and shifts in performance.

$$\%Deviation = \frac{\text{Your Result} - \text{Consensus Mean}}{\text{Consensus Mean}} \times 100\%$$



- 1 %Deviation from Mean for Comparison.
- 2 Plot of Running Mean %Deviations (average of the last 10 %Deviations for the sample indicated).
- 3 Acceptable limits of performance. These are defaulted to RIQAS TDPAs but can be set to e.g. biological variation or regulatory requirement on request.

The %Deviation by concentration chart enables rapid assessment of concentration related biases. Biases at low or high concentrations can be easily determined.



- 1 Current sample indicated by square.
- 2 %Deviation at specific concentration.

SUMMARY PAGE

Located at the back of the RIQAS Report, the Summary Page collates the key information, allowing participants to review the performance of all parameters at-a-glance.

| Analyte | Mean for Comparison | Your Result | SDI | RMSDI | %DEV | RM%DEV | TS | RMTS | Performance |
|----------------------|---------------------|-------------|---------------------|---------|---------------------|---------|------------------|------|-------------|
| Albumin | 2.120 | 2.230 | 1.00 | 0.37 | 5.2 | 2.0 | 72 | 107 | |
| Alkaline Phosphatase | 17.705 | 19.000 | 0.61 | -0.27 | 7.3 | -2.9 | 93 | 105 | |
| ALT (GPT) | 12.387 | 12.000 | -0.33 | -0.47 | -3.1 | -3.8 | 119 | 103 | |
| Amylase, Total | 20.454 | 22.000 | 0.72 | -0.29 | 7.6 | -2.5 | 86 | 103 | |
| AST (GOT) | 11.976 | 11.000 | -0.86 | -0.03 | -8.2 | -0.4 | 78 | 100 | |
| Bicarbonate | 8.203 | 6.900 | -1.48 | 0.15 | -15.9 | 1.5 | 54 | 98 | |
| Bilirubin, Direct | 0.251 | 0.380 | <u>2.57</u> | 2.64 | <u>51.3</u> | 47.2 | <u>31</u> | 29 | ▲ |
| Bilirubin, Total | 0.701 | 0.640 | -0.91 | -0.29 | -8.8 | -2.9 | 76 | 101 | |
| Calcium | 6.074 | 6.020 | -0.19 | -0.40 | -0.9 | -1.8 | 120 | 92 | |
| Chloride | 76.353 | 77.000 | 0.30 | -0.28 | 0.8 | -0.8 | 120 | 98 | |
| Cholesterol | 112.696 | 110.000 | -0.55 | 0.05 | <u>2.4</u> | 0.2 | 97 | 115 | |
| CK, Total | 111.659 | 111.000 | -0.08 | 0.35 | -0.6 | 2.5 | 120 | 107 | |
| Creatinine | 0.607 | 0.620 | 0.27 | 0.06 | 2.1 | 0.5 | 120 | 117 | |
| Glucose | 36.429 | 36.000 | -0.26 | -0.84 | -1.2 | -3.7 | 120 | 82 | |
| HDL-Cholesterol | 98.836 | 102.000 | 0.21 | -0.04 | 3.2 | -0.4 | 120 | 113 | |
| Iron | 97.374 | 99.000 | 0.28 | 0.01 | 1.7 | 0.1 | 120 | 114 | |
| Lactate | | No Result | | Too Few | | Too Few | N/A | N/A | |
| LD (LDH) | 85.894 | 87.000 | 0.11 | -0.70 | 1.3 | -6.3 | 120 | 89 | |
| Magnesium | 1.313 | 1.390 | 0.79 | -0.07 | 5.8 | -0.5 | 82 | 107 | |
| Phosphate, Inorganic | 1.451 | 1.540 | 1.02 | 0.02 | 6.1 | 0.1 | 71 | 112 | |
| Potassium | 1.770 | 1.840 | 1.10 | -0.25 | 3.9 | -0.7 | 67 | 99 | |
| Protein, Total | 3.850 | 3.830 | -0.11 | 0.07 | -0.5 | 0.3 | 120 | 114 | |
| Sodium | 112.537 | 114.000 | 0.58 | -0.01 | 1.3 | -0.0 | 95 | 104 | |
| TIBC | 133.143 | 133.000 | -0.01 | -0.01 | -0.1 | -0.1 | 120 | 117 | |
| Trig Total | 23.626 | 24.000 | 0.18 | -0.09 | 1.6 | -0.6 | 120 | 114 | |
| Urea | 5.872 | 5.000 | <u>-2.02</u> | -0.57 | <u>-14.9</u> | -4.0 | <u>41</u> | 95 | ▲ |
| Uric Acid (Urate) | 3.135 | 3.100 | -0.20 | -0.44 | -1.1 | -2.4 | 120 | 107 | |

ORMSDI -0.05

ORM%DEV 0.8

ORMTS 102

1 Red triangle appears when all performance indicators (SDI, %DEV and TS) exceed acceptable performance, i.e: when SDI >= 2
TS < 50
%DEV > acceptable limits set

2 RMSDI - is the Running Mean of the 10 previous SDIs (if fewer than 10 results on file, "Too Few" is printed).

3 RM %DEV - Average of the last 10 %DEV for this parameter.

4 RMTS - Average of the last 10 Target Scores for this parameter.

5 All poor performance is highlighted in bold and underlined.

6 Overall RMSDI = average RMSDI for this sample distribution.

7 Overall RM%DEV = average RM%DEV for this sample distribution.

8 Overall RMTS = average RMTS for this sample distribution.

END-OF-CYCLE QUANTITATIVE REPORT

The End-of-Cycle Report is sent to labs receiving standard reports at the end of each cycle and provides a complete summary of statistics. Results can also be compared to the previous cycle.





Albumin, g/l

Method: Bromocresol Purple
Instrument: Siemens/Dade Dimension RxL/Max/Xpand
Reagent: Siemens/Dade Behring

RIQAS TDPA: 7.1% **Biological Variation:** 3.9%

| Sample | Result | Unit | N | Mean for Comparison | CV% | Um | SDPA | SDI | TS | %Deviation |
|--------|--------|------|----|---------------------|-----|------|------|-------|-----|------------|
| 1 | 28.200 | g/l | 68 | I 28.013 | 2.4 | 0.10 | 1.26 | 0.15 | 120 | 0.67 |
| 2 | 26.900 | g/l | 87 | I 26.853 | 2.7 | 0.10 | 1.21 | 0.04 | 120 | 0.17 |
| 3 | 39.900 | g/l | 71 | I 40.531 | 2.5 | 0.15 | 1.82 | -0.35 | 118 | -1.56 |
| 4 | 19.200 | g/l | 81 | I 19.429 | 2.5 | 0.07 | 0.87 | -0.26 | 120 | -1.18 |
| 5 | 41.700 | g/l | 67 | I 41.859 | 2.0 | 0.13 | 1.88 | -0.08 | 120 | -0.38 |
| 6 | 57.300 | g/l | 87 | I 57.257 | 2.7 | 0.21 | 2.58 | 0.02 | 120 | 0.08 |
| 7 | 45.000 | g/l | 72 | I 45.850 | 2.1 | 0.14 | 2.06 | -0.41 | 110 | -1.85 |
| 8 | 27.600 | g/l | 87 | I 28.013 | 2.5 | 0.09 | 1.26 | -0.33 | 120 | -1.47 |
| 9 | 41.200 | g/l | 70 | I 41.891 | 2.2 | 0.14 | 1.88 | -0.37 | 115 | -1.65 |
| 10 | 26.900 | g/l | 83 | I 26.742 | 3.3 | 0.12 | 1.20 | 0.13 | 120 | 0.59 |
| 11 | 40.700 | g/l | 71 | I 40.601 | 2.2 | 0.14 | 1.83 | 0.05 | 120 | 0.24 |
| 12 | 45.100 | g/l | 80 | I 45.456 | 2.2 | 0.14 | 2.04 | -0.17 | 120 | -0.78 |
| 13 | 27.300 | g/l | 63 | I 28.179 | 2.0 | 0.09 | 1.27 | -0.69 | 87 | -3.12 |

| | Cycle 45 | Cycle 46 |
|-----------------------------|----------|----------|
| Cycle Average SDI | -0.23 | -0.18 |
| Cycle Average TS | 110 | 116 |
| Cycle Average %DEV | -1.05 | -0.79 |
| Cycle Average Absolute SDI | 0.36 | 0.24 |
| Cycle Average Absolute %DEV | 1.63 | 1.06 |



END-OF-CYCLE REPORT TEXT SECTION

The text section summarises the statistical information for all samples.

1 Albumin, g/l

Method: Bromocresol Purple
Instrument: Siemens/Dade Dimension RxL/Max/Xpand
Reagent: Siemens/Dade Behring

3 RIQAS TDPA: 7.1% **Biological Variation:** 3.9%

Your assay details at the end of the cycle. The RIQAS TDPA and biological variation for the parameter are shown if available.

- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14

| Sample | Result | Unit | N | Mean | SDPA | U _m | CV% | SDI | TS | % Deviation |
|--------|--------|------|----|----------|------|----------------|-----|-------|-----|-------------|
| 1 | 28.200 | g/l | 68 | I 28.013 | 1.26 | 0.10 | 2.4 | 0.15 | 120 | 0.7 |
| 2 | 26.900 | g/l | 87 | I 26.853 | 1.21 | 0.10 | 2.7 | 0.04 | 120 | 0.2 |
| 3 | 39.900 | g/l | 71 | M 40.531 | 1.82 | 0.15 | 2.5 | -0.36 | 116 | -1.5 |
| 4 | 19.200 | g/l | 81 | I 19.429 | 0.87 | 0.07 | 2.5 | -0.27 | 120 | -1.2 |
| 5 | 41.700 | g/l | 67 | I 41.942 | 1.88 | 0.13 | 2.0 | -0.09 | 120 | -0.4 |
| 6 | 57.300 | g/l | 87 | I 57.257 | 2.58 | 0.21 | 2.7 | 0.02 | 120 | 0.1 |
| 7 | 45.000 | g/l | 72 | I 45.850 | 2.06 | 0.14 | 2.1 | -0.43 | 108 | -1.8 |
| 8 | 27.600 | g/l | 87 | I 28.011 | 1.26 | 0.09 | 2.5 | -0.34 | 118 | -1.5 |
| 9 | 41.200 | g/l | 70 | I 41.823 | 1.88 | 0.14 | 2.2 | -0.38 | 113 | -1.6 |
| 10 | 26.900 | g/l | 83 | I 26.742 | 1.20 | 0.12 | 3.3 | 0.14 | 120 | 0.6 |
| 11 | 40.700 | g/l | 71 | I 40.601 | 1.83 | 0.13 | 2.2 | 0.06 | 120 | 0.2 |
| 12 | 45.100 | g/l | 80 | I 45.119 | 2.05 | 0.14 | 2.2 | -0.18 | 120 | -0.8 |
| 13 | 27.300 | g/l | 63 | I 28.454 | 1.27 | 0.09 | 2.0 | -0.72 | 86 | -3.1 |

Summary of your results and statistics are shown, including Mean for Comparison, SDPA, %CV, U_m, SDI, Target Score, %Deviation.

| | Cycle 45 | Cycle 46 |
|--------------------------------------|----------|----------|
| 15 Cycle Average SDI | -0.23 | -0.18 |
| Cycle Average TS | 110 | 116 |
| Cycle Average %DEV | -1.05 | -0.79 |
| 16 Cycle Average Absolute SDI | 0.36 | 0.24 |
| Cycle Average Absolute %DEV | 1.63 | 1.06 |

Table containing a summary of your performance for previous cycle and current cycle, including Average Absolute SDIs and %Deviations.

END-OF-CYCLE REPORT TEXT SECTION

- 1 Report presented in your chosen unit
- 2 Your assay details as of the last sample
- 3 RIQAS TDPA and Biological variation
- 4 Sample number
- 5 Your results for each sample
- 6 Unit your result was returned in
- 7 Number of results used for statistical analysis
- 8 Mean for Comparison (including comparison level)
- 9 SDPA = Standard Deviation for performance assessment
- 10 Uncertainty of Mean for Comparison
- 11 Coefficient of Variation (%)
- 12 Your Standard Deviation Index
- 13 Your Target Score
- 14 Your %Deviation

15 Cycle average of your performance indicators – Standard Deviation Index, Target Score and %Deviation.

$$\text{Cycle Average SDI} = \frac{\text{(Sum of SDIs returned for the completed cycle)}}{\text{(Number of samples returned in cycle)}}$$

$$\text{Cycle Average Target Score} = \frac{\text{(Sum of your Target Scores returned for the completed cycle)}}{\text{(Number of samples returned in cycle)}}$$

$$\text{Cycle Average \%Deviation} = \frac{\text{(Sum of your \%Deviations returned for the completed cycle)}}{\text{(Number of samples returned in cycle)}}$$


16 Cycle average for Absolute values of your SDI and %Deviation. Absolute values show how far a value is from zero regardless of the sign. This is an indication of the magnitude of accuracy.

$$\text{Cycle Average Absolute SDI} = \frac{\text{(Sum of your Absolute SDIs returned for the completed cycle)}}{\text{(Number of samples returned in cycle)}}$$

$$\text{Cycle Average Absolute \%Deviation} = \frac{\text{(Sum of your Absolute \%Deviations returned for the completed cycle)}}{\text{(Number of samples returned in cycle)}}$$

END-OF-CYCLE CHART SECTION REPORT

Your results for current cycle shown in various diagrams.



- 1** Levey-Jennings chart

Shows your SDIs for a full cycle.

 - Shows SDI (positive and negative)
 - x Shows absolute SDI
- 2** Target Score chart

Shows your Target Scores for a full cycle.
- 3** %Deviation by sample chart

Shows your %Deviations for a full cycle.


Acceptable limits equal to TDPA unless alternative limits are registered by the lab.

 - Shows %Deviation (positive and negative)
 - x Shows absolute %Deviation
- 4** %Deviation by Concentration chart

Shows your results for a full cycle.

END-OF-CYCLE CURRENT & PREVIOUS CYCLE ABSOLUTE SDIs REPORT

Based on the cycle average absolute SDI, this chart provides a visual representation of your laboratory's performance compared to the previous cycle.



- 1 **Parameter list** List of all parameters registered.
- 2 **Results for previous cycle** Indicated by open circle on the chart.
- 3 **Report title - Cycle Average Absolute SDI** This shows your performance this cycle compared to the previous cycle.
- 4 **Results for current cycle** Indicated by a closed circle on the chart.
- 5 **Legend** Cycle Average Absolute SDIs are shown for:

 - L Your results throughout the cycle
 - C All labs within your own country
 - W All labs Worldwide
- 6 **Graphical representation of Absolute SDIs** Acceptable performance is < 2.

If Absolute SDI for current cycle is less than that for the previous cycle, this is indicated by a green circle.

If Absolute SDI for current cycle is greater than that for the previous cycle, this is indicated by a red circle.

The closer the circle is to zero, the better the performance.

END-OF-CYCLE CERTIFICATE OF PERFORMANCE REPORT

An End-of-Cycle report will be issued for all registrations. However, the Certificate of Performance will only be available for parameters where results for at least 50% of samples in the cycle have been returned. Labs joining after the beginning of the cycle will only receive the Certificate of Performance if they meet this criterion. Any parameters not included on the Certificate of Acceptable Performance will be listed on the Notification of Unacceptable Performance.



RANDOX INTERNATIONAL QUALITY ASSESSMENT SCHEME

CERTIFICATE OF ACCEPTABLE PERFORMANCE

Laboratory Name
Laboratory Address
Country

1

2 LABORATORY REF. NO. 111/A

3 CLINICAL CHEMISTRY - CYCLE 66

4 05/09/2022


This is to certify that the above participant took part in a cycle of external quality assessment and achieved an acceptable level of performance (Cycle Average Absolute SDI < 2) for the following parameters:

| | 5 | 6 Cycle Average Absolute SDI |
|--|---|------------------------------|
| Albumin - Bromocresol Green - Abbott Alinity i | | 1.61 |
| Alkaline Phosphatase - AMP optimised to IFCC - Abbott Alinity c | | 0.80 |
| ALT (GPT) - Tris buffer without P5P - Abbott Alinity c | | 1.20 |
| Amylase, Total - Other 2-chloro-pNPG3 - Abbott Alinity c | | 0.99 |
| AST (GOT) - Tris buffer without P5P - Abbott Alinity c | | 0.50 |
| Bile Acids - Enzymatic Colorimetric - Abbott Alinity c | | 0.49 |
| Bilirubin, Direct - Diazo with Dichloroaniline - Abbott Alinity c | | 0.36 |
| Bilirubin, Total - Diazo with Dichloroaniline - Abbott Alinity c | | 0.72 |
| Calcium - Arsenazo - Abbott Alinity c | | 0.69 |
| Chloride - ISE, direct - Abbott Alinity c | | 1.08 |
| Cholesterol - Cholesterol Oxidase - Abell Kendall - Abbott Alinity c | | 0.63 |
| CK, Total - Abbott CK-NAC (IFCC) - Abbott Alinity c | | 0.47 |
| Creatinine - Alkaline picrate no deproteinisation - Abbott Alinity c | | 1.42 |
| GGT - Gamma glut.-3-carb.-4-nitro. - Abbott Alinity c | | 0.83 |
| Glucose - Hexokinase - Abbott Alinity c | | 0.75 |

| | | |
|---|---------------------------|---|
| 1 | Full registration address | Your full registration address details. |
| 2 | Your lab reference number | Used to identify each lab. |
| 3 | Programme / cycle number | Programme and current, completed cycle number. |
| 4 | Date | Date End-of-Cycle report is issued. |
| 5 | Parameters | List of parameters including the assay details for which cycle absolute SDI is < 2. |
| 6 | Average Absolute SDI | Your Cycle Average Absolute SDI. |

MULTI-INSTRUMENT REPORT

Register up to five instruments per programme at no extra cost. In addition to a standard report for each instrument, a multi-instrument report is also provided allowing comparative performance assessment.



- 1 Allowable %deviation for the parameter in question, based on the RIQAS TDPA.
- 2 Sample number.
- 3 Lab name.
- 4 Unique instrument ID.

- 5 Poor performance.
- 6 %Deviation for each individual sample.
- 7 RM %Dev - Average of the last 10 %Dev for this parameter.
- 8 %Deviation chart comparing the performance of each instrument.

URINE TOXICOLOGY REPORT

Laboratory performance is presented in both quantitative and qualitative screening formats, allowing for easy interpretation at-a-glance.


Screening Section

Quantitative Section

Amphetamines Group, ng/ml

Your Result Positive

Based on comparison value of 750
and your chosen cut-off value of 500
the correct response was Positive




All Methods
 KIMS

| N | Mean | CV% | U _m | SDPA | Exc. |
|----|----------|------|----------------|--------|------|
| 74 | 656.297 | 77.4 | 73.82 | 507.99 | 23 |
| 25 | 1344.540 | 15.1 | 50.82 | 203.30 | 2 |

| | | | |
|-----------------------|----------|-------|-------|
| ▲ Your Result | 1405.000 | SDI | 0.30 |
| | | RMSDI | -0.12 |
| ■ Mean for Comparison | 1344.540 | | |

| | | |
|---------------|------|-------|
| MDMA | 750 | ng/ml |
| Ethanol | 62.5 | mg/dl |
| EDDP | 75 | ng/ml |
| Free Morphine | 1500 | ng/ml |
| Nortriptyline | 375 | ng/ml |

| | Cut-off | TN | TP | FN | FP | RC | NT | Total |
|-------------------------------------|---------|----|----|----|----|----|----|-------|
| Your Result | 500 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| KIMS | 500 | 0 | 21 | 0 | 0 | 0 | 0 | 21 |
| | 1000 | 0 | 0 | 0 | 9 | 0 | 0 | 9 |
| | All | 0 | 21 | 0 | 9 | 0 | 0 | 30 |
| All Methods | 150 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| | 300 | 0 | 5 | 9 | 0 | 0 | 0 | 14 |
| | 500 | 0 | 32 | 49 | 0 | 0 | 0 | 81 |
| | 1000 | 65 | 0 | 0 | 10 | 0 | 3 | 78 |
| | All | 65 | 38 | 58 | 10 | 0 | 3 | 174 |
| Competitive Antibody Binding | 500 | 0 | 3 | 0 | 0 | 0 | 0 | 3 |
| CEDIA | 500 | 0 | 2 | 4 | 0 | 0 | 0 | 6 |
| DRI-EIA | 500 | 0 | 3 | 3 | 0 | 0 | 0 | 6 |
| ELISA | 500 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| EMIT | 500 | 0 | 1 | 27 | 0 | 0 | 0 | 28 |
| EMIT II+ | 500 | 0 | 0 | 8 | 0 | 0 | 0 | 8 |
| Point of Care | 500 | 0 | 0 | 5 | 0 | 0 | 0 | 5 |
| Quidel Triage | 500 | 0 | 2 | 1 | 0 | 0 | 0 | 3 |





| Method | N | Mean | CV% | U _m |
|------------------------------|----|----------|------|----------------|
| EMIT | 15 | 135.267 | 19.2 | 8.37 |
| KIMS | 25 | 1344.540 | 15.1 | 50.82 |
| DRI-EIA | 10 | 511.420 | 5.6 | 11.22 |
| EMIT II+ | 5 | 119.540 | 22.4 | 14.98 |
| CEDIA | 5 | 298.942 | 89.9 | 150.22 |
| Competitive Antibody Binding | 4 | 540.725 | 2.7 | 9.19 |
| ELISA | 3 | 501.033 | 4.9 | 17.73 |

Performance History

| Your Data (Last 10 Samples) | Your Method (This Sample) | Your Method (Last 10 Samples) | All Methods (This Sample) | All Methods (Last 10 Samples) |
|-----------------------------|---------------------------|-------------------------------|---------------------------|-------------------------------|
| 0 % False Negatives | 0 % False Negatives | 1 % False Negatives | 34 % False Negatives | 11 % False Negatives |
| 10 % False Positives | 30 % False Positives | 11 % False Positives | 6 % False Positives | 5 % False Positives |
| 90 % Correct Responses | 70 % Correct Responses | 88 % Correct Responses | 60 % Correct Responses | 83 % Correct Responses |

URINE TOXICOLOGY REPORT SCREENING SECTION

Qualitative comparison of screening results available for each parameter.




- Text section shows the correct response for the lab based on a comparison between the comparison value and the lab's cut off value.
- Screening Results:** This chart is a quick visualisation of your performance over the last 20 samples. A result in the white section indicates a correct response. A result in the upper red section indicates a False Positive response, and a result in the lower red section indicates a False Negative response.
- Comment section for RIQAS to provide your laboratory with additional relevant information regarding this sample, such as spiked metabolite concentration.
- Screening result response categories. All abbreviations indicated at the bottom of the report page.
Key
TN - true negative TP - true positive FN - false negative
FP - false positive RC - sent for confirmation NT - not tested
- Screening Summary:** Your screening result shown in the appropriate response category and your cut off for this sample.
- Screening results for all cut-offs returned for this sample within your method group.

- Total screening results over all cut-offs for your laboratory's method.
- Screening results for all cut-offs returned for this sample over all methods.
- Total screening results over all cut-offs for all methods.
- Screening results for other methods using same cut-off as your laboratory.
- Performance history for this parameter, based on previous 10 samples.
- Performance of your method over all cut-offs for this sample.
- Performance history of your method over all cut-offs, based on the previous 10 samples.
- Performance of all methods over all cut-offs for this sample.
- Performance history of all methods over all cut-offs, based on the previous 10 samples.

URINE TOXICOLOGY REPORT QUANTITATIVE SECTION

Quantitative statistical comparison available for each parameter.



1 **Quantitative Text Section:** Comparison statistics. Caution is needed when the N value is too small to support statistical significance.

2 Your Result.

3 Your Mean for Comparison.

4 **Standard Deviation Index** =
$$\frac{\text{Your Result} - \text{Mean for Comparison}}{\text{SD of Mean for comparison}}$$


5 Running mean SDI = average of last 10 SDIs for this parameter (If fewer than 10 results, "Too Few" is printed).

6 **Quantitative Results Histogram:** This graph provides a quick visualisation of how your quantitative result falls into the overall picture for all methods and your method group.

7 All available method statistics for this sample.

URINALYSIS REPORT

Your performance for each parameter is presented in a simple, convenient report.



- 1 Categories are stated in your unit.
- 2 Your method group.
- 3 Your categories (available result options for chosen test strip and unit).
- 4 All categories (result options) available for this parameter for any method (test strip).
- 5 Results from all methods (test strips) returning results in the same categories as your lab.
- 6 Your Result.
- 7 **Your Score:** Scores between 0-6 are acceptable, 7 borderline and 8-10 unacceptable.
- 8 Target categories and percentages of submitted results in that categories. Target categories are based on 80% consensus in the results in your categories. Multiple categories may be used to make up the 80% consensus. Target categories are highlighted by * in text section.
- 9 Performance Statement.
- 10 **Historical Performance:** Provides number of correct scores and acceptable assessments for the last 6 samples.
- 11 **Categories Histogram:** A quick visualisation of how your lab's result falls into the overall picture for your categories.
- 12 Possible reporting categories for your method. Target categories are highlighted by *.
- 13 Your result is indicated by the black triangle.
- 14 **Levey-Jennings type chart:** Acceptable scores (0-6) have no shading, borderline scores (7) have light red shading, unacceptable scores (8-10) have dark red shading.
- 15 Score for each sample number.
- 16 Sample Number.
- 17 **Target Categories:** If there was more than 1 target category assigned for a sample Multi is stated.
- 18 All methods reported for this parameter.
- 19 **Detailed summary of results:** This table enables you to see how you compare to all other results.

SEROLOGY REPORT




Laboratory performance is presented in both quantitative and qualitative screening formats, allowing for easy interpretation at-a-glance.

Anti-Rubella IgG, IU/ml

| | N | Mean | CV% | U _m | SDPA | Exc. |
|---------------------------|-----|--------|------|----------------|-------|------|
| All Methods | 268 | 49.505 | 50.3 | 1.90 | 24.90 | 19 |
| Abbott Architect/ Alinity | 86 | 29.416 | 5.2 | 0.21 | 1.53 | 10 |

| | | | |
|-------------------------|----------|-------|-------|
| ▲ Your Result | 27,800 | SDI | -1.06 |
| Your Qualitative Result | Reactive | RMSDI | 0.00 |
| ■ Mean for Comparison | 29,416 | | |

| | |
|-----------------------------|---------------------------|
| Your method: | Abbott Architect/ Alinity |
| Your result: | Reactive |
| Acceptable result (Method): | Reactive |
| Overall results | |
| Non-Reactive: | 2 |
| Inconclusive: | 0 |
| Reactive: | 278 |




| Method | N | Non-Reactive | Inconclusive | Reactive |
|------------------------------------|----|--------------|--------------|----------|
| Abbott Architect/ Alinity | 94 | 0 | 0 | 94 |
| Roche Cobas e601/ 602 | 41 | 0 | 0 | 41 |
| BioMerieux VIDAS | 25 | 0 | 0 | 25 |
| Roche Cobas 4000/e411 | 22 | 0 | 0 | 22 |
| Roche Cobas e402/e801 | 21 | 0 | 0 | 21 |
| DiaSorin Liaison XL | 14 | 0 | 0 | 14 |
| Siemens Atellica IM | 10 | 0 | 0 | 10 |
| Siemens/DPC Immulite 2000/2500 | 9 | 0 | 0 | 9 |
| Ortho Vitros 3600/5600/ECi/XT 7600 | 9 | 1 | 0 | 8 |
| Beckman Dxl 600/800 | 6 | 0 | 0 | 6 |
| DiaSorin, Liaison | 6 | 1 | 0 | 5 |
| Siemens Centaur XP/XPT | 5 | 0 | 0 | 5 |
| Siemens Centaur XP/XPT RbGII | 5 | 0 | 0 | 5 |
| SNIBE Maglumi analysers | 4 | 0 | 0 | 4 |
| Siemens Atellica IM RbGII | 3 | 0 | 0 | 3 |

| Method | N | Mean | CV% | U _m |
|------------------------------------|----|---------|------|----------------|
| Abbott Architect/ Alinity | 86 | 29.416 | 5.2 | 0.21 |
| Roche Cobas e601/ 602 | 38 | 82.481 | 5.8 | 0.97 |
| BioMerieux VIDAS | 25 | 46.540 | 7.7 | 0.89 |
| Roche Cobas 4000/e411 | 22 | 81.417 | 7.1 | 1.54 |
| Roche Cobas e402/e801 | 21 | 92.786 | 5.0 | 1.26 |
| DiaSorin Liaison XL | 15 | 33.353 | 8.4 | 0.90 |
| Siemens Atellica IM | 9 | 225.947 | 10.8 | 10.19 |
| Siemens/DPC Immulite 2000/2500 | 9 | 35.522 | 9.8 | 1.45 |
| Ortho Vitros 3600/5600/ECi/XT 7600 | 8 | 49.850 | 14.4 | 3.18 |
| Beckman Dxl 600/800 | 7 | 37.774 | 14.0 | 2.49 |
| DiaSorin, Liaison | 5 | 35.180 | 5.9 | 1.17 |
| Siemens Centaur XP/XPT | 3 | 283.233 | 12.0 | 24.50 |
| Siemens Centaur XP/XPT RbGII | 5 | 33.846 | 8.0 | 1.50 |
| SNIBE Maglumi analysers | 4 | 10.088 | 4.2 | 0.27 |
| Siemens Atellica IM RbGII | 3 | 34.117 | 3.5 | 0.87 |

SEROLOGY: QUALITATIVE REPORT

Your performance for each sample is presented in a convenient single page per parameter report format.



1 Your qualitative result and chosen method are presented along with the acceptable result based on an 80% consensus. This consensus will be at the method level if there are ≥ 5 labs in the group or if there are < 5 labs, will be at the all method level.

2 Overall Summary shows the number of results for this parameter and sample which are non-reactive, inconclusive or reactive.


3 Your Result is shown as a black triangle on the category chart compared to other laboratories in groups:

All Methods Your Method

4 Summary shows performance of all the methods used to analyse the parameter.

SEROLOGY: SCREENING (QUANTITATIVE) REPORT

Your performance for each sample is presented in a convenient single page per parameter report format.



1 Quantitative statistics for All Methods and Your Method are presented in your chosen unit along with your result and your performance scores (SDI and RMSDI).

2 **Levey-Jennings chart** - Your SDIs for previous 20 samples.

3 Your result is presented on the bar graph as a black triangle, showing how you compare to:

All Methods Your Method

4 Multi Method Statistics section provides an easy way of assessing the performance of the methods used to analyse the parameter.

SERUM INDICES: SUMMARY PAGE

The RIQAS Serum Indices EQA programme is designed for the pre-analytical assessment of Haemolytic, Icteric and Lipemic (HIL) interferences. HIL parameters include the option of quantitative or semi-quantitative reporting. Interpretation of chemistry parameter results is also included for a number of parameters. The summary page collates the key information on both the quantitative and qualitative results for the HIL parameters.

| Sample 1 - Normal | | | | | |
|-----------------------|------------------|---------------------|-------------|-------|-------|
| Sample 2 - Haemolytic | | | | | |
| Sample 3 - Lipaemic | | | | | |
| Sample | Analyte | Mean for Comparison | Your Result | SDI | %DEV |
| 1 | Haemolytic Index | 13.750 | 14.000 | 0.02 | 1.8 |
| | Icteric Index | 0.980 | 1.100 | 0.17 | 12.2 |
| | Lipaemic Index | 13.600 | 8.000 | -0.83 | -41.2 |
| 2 | Haemolytic Index | 469.000 | 500.000 | 0.34 | 6.6 |
| | Icteric Index | 2.475 | <2.500 | | |
| | Lipaemic Index | 40.000 | 45.000 | 1.23 | 12.5 |
| 3 | Haemolytic Index | 53.000 | <50.000 | | |
| | Icteric Index | 5.700 | 6.100 | 0.28 | 7.0 |
| | Lipaemic Index | 42.000 | <40.000 | | |

| Sample | Analyte | Target Categories | Your Result | Your Score |
|--------|------------------|-------------------|-------------|------------|
| 1 | Haemolytic Index | 0 | 0 | 0 |
| | Icteric Index | 0 | 0 | 0 |
| | Lipaemic Index | 0 | 0 | 0 |
| 2 | Haemolytic Index | 4+ 5+ | 5+ | 0 |
| | Icteric Index | 0 | 0 | 0 |
| | Lipaemic Index | 0 | 1+ | 1 |
| 3 | Haemolytic Index | 0 | 0 | 0 |
| | Icteric Index | 2+ | 2+ | 0 |
| | Lipaemic Index | 0 | 0 | 0 |

1 The first section shows the status of each of the samples i.e. if the sample is a normal sample or if it is haemolytic, icteric or lipaemic.

2 The next section shows the summary of the quantitative results for the Serum Indices and your performance (SDI and %DEV) for each sample.

3 The final section shows the summary of the semi-quantitative results for the Serum Indices. This includes the target categories based off an 80% consensus in the results, your result and your score for each of the samples.

SERUM INDICES REPORT

The summary section is followed by report pages for the 3 serum indices parameters. There will be 3 pages for each index – one for each sample.

Quantitative Section

Semi-quantitative Section

Icteric Index, mg/dl

1 Sample 18 Icteric

| | N | Mean | CV% | U _m | SDPA | Exc. |
|------------------|----|--------|-----|----------------|-------|------|
| All Methods | 77 | 11.036 | 7.5 | 0.12 | 0.82 | 7 |
| Abbott Alinity | 17 | 11.978 | 4.2 | 0.15 | 0.52a | 1 |
| Abbott Alinity c | 17 | 11.978 | 4.2 | 0.15 | 0.52a | 1 |

| | | | |
|-----------------------|--------|------|-------|
| ▲ Your Result | 11.800 | SDI | -0.34 |
| ■ Mean for Comparison | 11.978 | %DEV | -1.5 |

| | 0 | 1+ | 2+ | 3+ | 4+ | 5+ | 6+ | 7+ |
|-------------|---|----|----|----|----|----|----|----|
| All Methods | 2 | 1 | 7 | 18 | 1 | 0 | 1 | 0 |
| IIAAC* | 0 | 0 | 0 | 9 | 0 | 0 | 0 | 0 |

▲ Your Result 3+ Your Score 0

Target Categories 3+

* IIAAC = Abbott Alinity

Number of Laboratories vs mg/dl

Mean for Comparison: 11.978

Number of Laboratories vs Categories

Your Result: 3+


Standard Deviation vs Sample Number

Variation from Target vs Sample Number

1 Under the Serum Index parameter name the report will display the sample status e.g. if the sample should be flagging as haemolytic, icteric or lipaemic. As with all reports, the results contained within the report pages will be in the unit selected by the lab during the registration process.

SERUM INDICES REPORT: QUANTITATIVE SECTION

Quantitative comparison of results available for each index.




1 Text Section: In the text section you will see the All method, method and instrument means for comparison in addition to the respective statistics. Below this you will see your result, your Mean for comparison and your performance (SDI and %DEV) for this specific sample. For samples which do not hit specific flags for the indices, a large proportion of analysers will have a less than (<) setting. On a RIQAS report these will be counted in the excluded column. As one sample in each distribution will be a normal sample, it is likely there will be a large number of (<) results returned for these samples so we are indicating in this section the percentage of results that have been returned as a < or > result to allow labs to see if the number of excluded results is high that there is an explanation for this.

2 Histogram: As with other RIQAS reports, this histogram shows an overview of the spread of the results that have been returned for each level of comparison (all method (white), method (green) and instrument (blue)). The lab's result is indicated by the black triangle at the bottom of the chart.

3 Levey Jennings style chart: The Levey Jennings chart will display the lab's SDIs. These reflect laboratory performance in relation to SDPAs and are useful to monitor performance over time. Acceptable performance is SDI < 2. The sample numbers will be displayed along the bottom of the chart and the Means for Comparison including the level will be displayed along the top of the report.

SERUM INDICES REPORT: SEMI-QUANTITATIVE SECTION

Semi-quantitative comparison of the results available for each parameter.



1 Text Section: This shows the breakdown of the semi-quantitative results returned – broken down by all methods and the labs chosen method. The method is displayed as a code, the description for which is found in the box just below containing the lab’s result.

The lab’s result, target categories (based on an 80% consensus), and the lab’s score based on how many categories away from the target category the result is, are displayed below the breakdown of each category.


2 Histogram: The histogram shows a pictorial breakdown of the results returned for each category. The lab’s result is indicated by the black triangle at the bottom of the chart.

3 Levey-Jennings chart: This chart will display the lab’s score or variation from the target category.

The sample numbers will be displayed along the bottom of the chart and the target categories along the top. If there is more than one target category, the chart will display the word ‘Multi’.

SERUM INDICES REPORT: CHEMISTRY PARAMETER PAGE

Following the report pages for the 3 Serum Indices, there are the report pages for any chemistry parameters labs have registered for. There are 2 pages for each parameter, one showing the comparison between the first sample (the normal sample) and the second sample and the second page showing the comparison between the first and third sample respectively.



1 Sample Status: Under the chemistry parameter name the report will display the sample status e.g. if the sample should be flagging as haemolytic, icteric or lipaemic for the 2 samples being compared. As with all reports, the results contained within the report pages will be in the unit selected by the lab during the registration process.

The rest of the report page shows the same information for each of the 2 samples being compared.

The first sample of the 3 in each distribution will be the normal sample, the other 2 may or may not flag for one or more of the Indices.

2 Text Section: In the text section you will see the all method, method and instrument means for comparison and the respective statistics. Below this you will see you result, your Mean for comparison and your performance (SDI and %DEV) for this specific sample.

The % shift in the Means for Comparison between the normal and the affected sample is displayed in the results box for the second and third sample.

3 Histogram: As with other RIQAS reports, this histogram shows an overview of the spread of the results that have been returned for each level of comparison (all method (white), method (green) and instrument (blue)). The lab's result is indicated by the black triangle at the bottom of the chart.

4 Method Summary Section: As with other RIQAS reports, this section provides an easy way of assessing the performance of other methods used to analyse the parameter in question. The code at the beginning of the description is the key to the following section - Reporting of the Result based on Serum Indices flag.

5 Reporting of the Result based on Serum Indices flag: Depending on the Index that has been flagged, the lab may choose to not report the result to the clinician. In this section the lab can report on whether they would report the result for this parameter based on the result from the Serum Indices analysis.

BACTERIAL IDENTIFICATION REPORT

Presented in a convenient single report, all results for the current sample will be displayed within 6 sections.

Number of expected organisms in this sample: 1

| | |
|--|------------------------|
| Expected Organism: | Pseudomonas aeruginosa |
| Your Result for this Organism: | Pseudomonas aeruginosa |
| Result sent for referral (as per laboratory protocol)? | No |

Case study - A 41 year old fireman was badly burned during a house fire. This organism was cultured from his subsequently infected wound.

| | | | |
|---------------------------------|-------------------------------|-----------------------|--------------------|
| Current Performance | | Score Averages | |
| Your Score for this Organism: 3 | Correct Assessment (N) | Overall | Your Method |
| | Global | 125 | 2.84 |
| | Country | 22 | 2.92 |

Organisms Reported

Expected Organism: Pseudomonas aeruginosa

| Organism | No. of Results |
|-------------------------|----------------|
| Pseudomonas aeruginosa | 125 |
| Pseudomonas | 3 |
| Escherichia coli | 1 |
| Proteus | 1 |
| Pseudomonas fluorescens | 1 |
| Staphylococcus aureus | 1 |

Methods in Use

| Method | Incorrect | Partial | Correct |
|-------------------------|-----------|---------|------------|
| All Methods | 3 | 6 | 125 |
| Conventional tests | 3 (3.3) | 6 (6.7) | 81 (90.0) |
| VITEK 2 (all models) | 0 (0.0) | 0 (0.0) | 32 (100.0) |
| BD Phoenix (all models) | 0 (0.0) | 0 (0.0) | 6 (100.0) |
| MicroScan WalkAway | 0 (0.0) | 0 (0.0) | 3 (100.0) |
| Sensititre Aris 2X | 0 (0.0) | 0 (0.0) | 3 (100.0) |

BACTERIAL IDENTIFICATION REPORT

Participants can quickly and easily identify their performance for the current sample against their peers across geographic locations and those utilising same methodologies. Each section is explained in further detail below.

Number of expected organisms in this sample: 1

| | |
|---|------------------------|
| Expected Organism: | Pseudomonas aeruginosa |
| Your Result for this Organism: | Pseudomonas aeruginosa |
| Result sent for referral (as per laboratory protocol)? | No |

Case study - A 41 year old fireman was badly burned during a house fire. This organism was cultured from his subsequently infected wound.

| | | | |
|---------------------------------|-------------------------------|-----------------------|--------------------|
| Current Performance | | Score Averages | |
| Your Score for this Organism: 3 | Correct Assessment (N) | Overall | Your Method |
| | Global | 2.84 | 2.76 |
| | Country | 2.95 | 2.92 |

1 Sample Results: This shows the expected organism, the labs selected organism and information on the laboratory protocol being followed. Information on the lab's protocol will have an effect on the scoring for this sample.

2 Case Study: Clinical details are provided for each sample.

3 Performance Scoring: This will contain the lab's specific score for this sample. It will also show the correct assessments and overall scoring with the lab's country and globally.

If sample is NOT sent for referral, scoring is marked out of 3


- Correct Genus + species = 3
- Correct Genus + species is blank, if this is lab protocol = 3
- Correct Genus + species is blank = 1
- Correct Genus + incorrect species = 1
- Incorrect Genus and species but correct Gram stain = 0
- Incorrect Genus, species and Gram stain = -1

If sample is sent for referral, scoring is marked out of 2


- Correct Genus + species = 2
- Correct Genus + species is blank, if this is lab protocol = 2
- Correct Genus + species is blank = 1
- Correct Genus + incorrect species = 1
- Incorrect Genus and species but correct Gram stain = 0
- Incorrect Genus, species and Gram stain = 0

BACTERIAL IDENTIFICATION REPORT

4



5



6

| Method | Incorrect | Partial | Correct |
|-------------------------|-----------|---------|------------|
| All Methods | 3 | 6 | 125 |
| Conventional tests | 3 (3.3) | 6 (6.7) | 81 (90.0) |
| VITEK 2 (all models) | 0 (0.0) | 0 (0.0) | 32 (100.0) |
| BD Phoenix (all models) | 0 (0.0) | 0 (0.0) | 6 (100.0) |
| MicroScan WalkAway | 0 (0.0) | 0 (0.0) | 3 (100.0) |
| Sensititre Aris 2X | 0 (0.0) | 0 (0.0) | 3 (100.0) |

4

Bar Chart of Organisms Reported: This will list all organisms reported by each lab ordered in descending frequency. The black triangle indicates the lab's result.

5


Bar Chart Detailing Methods Used: This will list all methods used by each lab ordered in descending frequency. The bars are colour coded to highlight correct, partial and incorrect responses for each method. The black triangle indicates the lab's result.

6

Method Summary Section: This is a table providing the number of responses by method. The figures in brackets indicate the percentage of responses for each method.

BACTERIAL IDENTIFICATION - HISTORICAL PERFORMANCE

Track your performance across the previous 12 specimens using this one-page report.



- 1 This shows the lab's score across the last 6 samples. This score is also shown as a percentage.
- 2 This shows the percentages for the lab's country and globally for the last 6 samples. This is broken down by the lab's method and all methods.

- 3 A chart showing the lab's historical performance score. The expected organism for each sample is displayed along the top of the chart.
- 4 A chart showing the percentages for the lab, their country and globally. Each plot is the percentage score for 6 rolling samples.

ANTIMICROBIAL SUSCEPTIBILITY TESTING

Antimicrobial susceptibility testing table details all reported antibiotics for current sample and AST response.

| Antimicrobial Susceptibility Testing | | | | | |
|---|------------------|---------------------|------------------|----------------------------|------------------|
| Organism: Pseudomonas aeruginosa | | | | | |
| Antibiotic | Resistant | Intermediate | Sensitive | Your Result (Score) | Target |
| Amikacin | 2 | 2 | 107 | Sensitive (2/2) | Sensitive (Y) |
| Amoxicillin | 2 | 0 | 0 | | Too Few |
| Amoxicillin/Clavulanic Acid | 2 | 0 | 0 | | Too Few |
| Ampicillin | 6 | 0 | 1 | | Resistant (A) |
| Ampicillin/Sulbactam | 1 | 0 | 1 | | Too Few |
| Azithromycin | 0 | 1 | 0 | | Too Few |
| Aztreonam | 1 | 9 | 15 | Intermediate (N/A) | N/A |
| Cefazolin | 3 | 1 | 0 | | Too Few |
| Cefepime | 2 | 25 | 68 | Intermediate (2/2) | Intermediate (Y) |
| Cefixime | 2 | 0 | 0 | | Too Few |
| Cefodime | 0 | 2 | 3 | | Too Few |
| Cefoperazone | 0 | 0 | 1 | | Too Few |
| Cefoperazone/Sulbactam | 0 | 0 | 1 | | Too Few |
| Cefotaxime | 8 | 0 | 0 | | Resistant (A) |
| Cefoxitin | 1 | 0 | 1 | | Too Few |
| Cefpodoxime | 1 | 0 | 1 | | Too Few |
| Ceftazidime | 1 | 29 | 80 | Intermediate (1/2) | Sensitive (A) |
| Ceftazidime/Avibactam | 0 | 0 | 5 | | Sensitive (A) |
| Ceftolozane/Tazobactam | 0 | 1 | 6 | | Sensitive (A) |
| Ceftriaxone | 2 | 0 | 0 | | Too Few |
| Cefuroxime | 3 | 0 | 0 | | Too Few |
| Ciprofloxacin | 0 | 33 | 85 | Intermediate (2/2) | Intermediate (Y) |
| Clindamycin | 0 | 0 | 1 | | Too Few |
| Colistin | 1 | 6 | 17 | | Sensitive (Y) |
| Cotrimoxazole | 1 | 0 | 0 | | Too Few |
| Doripenem | 0 | 0 | 6 | | Sensitive (A) |
| Doxycycline | 1 | 0 | 0 | | Too Few |
| Ertapenem | 2 | 0 | 0 | | Too Few |
| Erythromycin | 0 | 0 | 1 | | Too Few |
| Fosfomycin | 4 | 0 | 0 | | Too Few |
| Gentamicin | 6 | 5 | 80 | Sensitive (2/2) | Sensitive (Y) |
| Imipenem | 13 | 27 | 57 | Intermediate (2/2) | Intermediate (Y) |
| Levofloxacin | 3 | 15 | 25 | Intermediate (N/A) | N/A |

- Target based on 80% agreement or at least 30% more than next common response
- Target requires at least 5 responses or else 'Too Few' is recorded
- Target is based initially on lab's guideline (Y) followed by all guidelines (A) if lab's guideline does not fulfil criteria. If neither of these are met then target recorded as N/A
- Participant responses are recorded for each antibiotic
- Participant responses from an incorrectly or partially identified organism are not included in totals

Scoring

- **If target is Sensitive**

- Response of sensitive = 2
- Response of intermediate = 1
- Response of resistant = 0

- **If target is Resistant**

- Response of sensitive = -1
- Response of intermediate = 1
- Response of resistant = 2

- **If target is Intermediate**

- Response of sensitive = 1
- Response of intermediate = 2
- Response of resistant = 1

- **No scoring possible if target is N/A or Too Few**

ANTIMICROBIAL SUSCEPTIBILITY TESTING

Antimicrobial susceptibility testing table details all reported antibiotics for current sample and AST response.

| | | | | | |
|---|------------------|---|-------|--------------------|------------------|
| Ticarcillin/Clavulanic Acid | 0 | 7 | 1 | Intermediate (2/2) | Intermediate (A) |
| Tigecyclin | 11 | 0 | 0 | | Resistant (A) |
| Tobramycin | 1 | 0 | 53 | Sensitive (2/2) | Sensitive (Y) |
| Trimethoprim/Sulfamethoxazole | 6 | 2 | 1 | | N/A |
| Vancomycin | 0 | 0 | 1 | | Too Few |
| 1 Your Score | | | | | |
| | 19 out of 20 | | 95.0% | | |
| Your Guideline: EUCAST | | | | | |
| | 350 out of 456 | | 76.8% | | |
| All Guidelines | | | | | |
| | 1755 out of 2048 | | 85.7% | | |
| 3 of your antibiotics have no target and are not scored | | | | | |

1 Scoring Summary

- A total score for the participants responses that had targets is provided for the participant

Your Score

- A total score for all antibiotics that had targets is provided for

**Your Guideline
All Guidelines**

Cefepime

| Guideline | Resistant | Intermediate | Sensitive | % Agreement |
|-------------|-----------|--------------|-----------|-------------|
| CLSI | 0 | 0 | 31 | 100.0% |
| EUCAST | 1 | 16 | 7 | 66.7% |
| Unspecified | 1 | 9 | 30 | 75.0% |

2 Guideline Analysis

- For each antibiotic that has a target assigned, a breakdown of the responses per guideline is provided

MONITORING EQA PERFORMANCE


Each EQA report should be evaluated and any poor performance investigated. A step by step approach should be adopted consisting of the following three steps:

1. Investigate the source of the problem

In order to identify the source of the problem, it is useful to be aware of the most common causes of poor EQA performance. Errors can occur at any stage of the testing process; however, EQA is most concerned with detecting analytical errors i.e. errors that occur during the analysis of the sample.

Most analytical errors can be easily divided into three main areas; clerical errors, systematic errors and random errors. Systematic errors result in inaccurate results that consistently show a positive or negative bias. Random errors, on the other hand, affect precision and result in fluctuations in either direction.

It may be possible that, after extensive investigations, the root cause of the poor performance cannot be established. Poor performance for a single sample could be attributed to random error. If poor performance has been noted for several samples, a systematic error is the most likely cause and the analytical process should be reviewed.



Clerical errors

- Transcription errors
- Incorrect units used
- Incorrect sample tested
- Incorrect method classification
- Calculation/conversion error

Systematic errors

- Sample/Reagent prep/handling
- Reagent/calibrator/standardisation change
- Instrument/reagent/calibrator fault
- Inexperienced operators
- Reagent deterioration
- Inappropriate method

Random errors

- Bubbles in reagent
- Bubbles in reagent/sample pipette
- Temperature fluctuations
- Poor pipetting technique
- Poor operator technique

The flowchart (page 29) is designed to help you investigate any apparent poor performance.

2. Implement corrective actions

Some errors can be readily recognised as simple clerical errors and easily corrected. If there is evidence of systematic or random error however more detailed corrective actions must be taken.

Systematic Error

In the event of a systematic error, the following suggested actions may help to resolve the problem:

- Perform instrument maintenance
- Recalibrate instrument
- Review reagent/sample storage
- Check pipettes
- Prepare fresh reagents & re-run sample
- Perform staff training

Random Error

If all possible causes have been excluded, a single unacceptable result is most likely due to random error. Re-run the sample; if the result of repeat analysis is acceptable then corrective action is not required. If the issue persists, investigate possible sources of systematic error.

3. Check the effectiveness of corrective actions

The effectiveness or impact of any corrective actions taken can be assessed by continuing to monitor analytical performance over time.

MONITORING EQA PERFORMANCE

A checklist similar to the one below is extremely useful when investigating poor EQA performance and may help you to determine the root cause of the problem and initiate corrective actions.

Laboratory:.....
 Cycle Number:..... Sample Number:.....
 Analysis Date:..... Analyte:.....
 Mean for Comparison:..... Lab Result:..... SDI:..... %Dev:.....

1. Specimen Handling

- a. Samples received in good condition Y N
- b. Samples stored/prepared appropriately Y N
- c. Integrity of the sample is acceptable Y N

2. Clerical

- a. Correct result entered Y N
- b. Correct use of decimal point and units Y N
- c. Calculations, if any, performed correctly (even if automated) Y N
- d. Conversion factors applied to results before submission Y N

3. Registration and Mean for Comparison

- a. Registered in the correct method/instrument group Y N
- b. Changed method or instrument without advising RIQAS Y N
- c. Peer Group changed due to the number of participants returning results e.g. from method to instrument Y N
- d. An obvious bias between method and instrument means (check histogram and stats sections) Y N

4. Internal Quality Control

- a. %Deviation of IQC (at similar conc to that of EQA) on sample analysis date acceptable Y N
- b. Shift in IQC in the periods just before and after EQA sample analysis Y N
- c. Trends in IQC in the periods before and after EQA sample analysis Y N
- d. Random IQC variation on sample analysis date Y N

Conclusion:.....

Lab Manager:..... Date:.....

Sample Number:.....
 Analyte:.....
 Lab Result:..... SDI:..... %Dev:.....

- e. Error due to imprecision; check IQC in terms of %Deviation compared to deviation observed in EQA Y N
- f. IQC target correctly assigned Y N

5. Calibration

- a. Date of last calibration
- b. Calibration frequency acceptable Y N
- c. Last calibration acceptable Y N

6. Instrument

- a. Daily maintenance performed on date of sample analysis Y N
- b. Special maintenance performed prior to sample analysis Y N
- c. Instrument operated correctly Y N
- d. Operator fully trained Y N

7. Reagents

- a. Reagents prepared and stored correctly Y N
- b. Reagents within open vial stability Y N

8. EQA sample


- a. Initial value
- b. Re-run value
- c. Issue observed in previous EQA samples at a similar concentration (check %Deviation by concentration and Levey Jennings charts) Y N
- d. All parameters affected (to the same extent) - possible reconstitution error (check %Deviation on summary pages) Y N

Remedial Action:.....

Lab Director:..... Date:.....

MONITORING EQA PERFORMANCE

The flow chart below can be used to help identify a possible root cause for poor EQA performance.



Ammonia/Ethanol Programme *With target scoring*

RQ9164 (2 ml)
2 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription

Ammonia Ethanol

Anti-Müllerian Hormone (AMH) Programme+

RQ9198 (1 ml)
1 Parameter
Samples every month, 1 x 12 month cycle, 12 month subscription

Anti-Müllerian Hormone (AMH)

Anti-TSH Receptor Programme+ *With target scoring*

RQ9174 (1 ml)
1 Parameter
Samples every month, 1 x 12 month cycle, 12 month subscription

Anti-TSH Receptor (TRAb)

Blood Gas Programme *With target scoring*

| | |
|---|---|
| RQ9134 (1.8 ml) First registered instrument 11 Parameters Samples every month, 1 x 12 month cycle, 12 month subscription | RQ9134/A (1.8 ml) Subsequent instruments 11 Parameters 12 month subscription |
|---|---|

| | | | |
|------------------|-------------------------|------------------|-----------------|
| Bicarbonate | CO ₂ (Total) | K+ | pH |
| Ca ⁺⁺ | Glucose | Na+ | pO ₂ |
| Cl- | Lactate | pCO ₂ | |

BNP Programme+ *With target scoring*

RQ9165 (1 ml)
1 Parameter
Samples every month, 1 x 12 month cycle, 12 month subscription

BNP

Cardiac Programme *With target scoring*

| | | |
|--|--------------------------------------|--|
| RQ9127/a (1 ml) 2 Parameters only (choose from 7) Samples every 2 weeks, 2 x 6 monthly cycles, 12 month subscription | RQ9127/b (1 ml) Full 7 Parameters | RQ9186 (1 ml) Full 7 Parameters Samples every month, 1 x 12 monthly cycle, 12 month subscription |
|--|--------------------------------------|--|

| | | | |
|------------------|--------------|------------|------------|
| CK, Total | CK-MB (Mass) | Myoglobin | Troponin T |
| CK-MB (Activity) | Homocysteine | Troponin I | |

Cardiac Plus Programme *With target scoring*

RQ9190 (3 ml)
11 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription

| | | | |
|----------------|--------------|-----------|------------|
| CK, Total | D-dimer | hsCRP | Troponin I |
| CK-MB Activity | Digoxin | Myoglobin | Troponin T |
| CK-MB Mass | Homocysteine | NT proBNP | |

Cerebrospinal Fluid Programme+ *With target scoring*

RQ9168 (3 ml)
7 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription

| | | | |
|----------|---------|-----------------|--------|
| Albumin | Glucose | Lactate | Sodium |
| Chloride | IgG | Protein (Total) | |

RIQAS PROGRAMMES

Coagulation Programme *With target scoring*

RQ9135/a (1 ml)
5 Selected parameters only + 1 pilot
(aPTT, PT, TT, Fibrinogen, Antithrombin III)
Samples every month, 1 x 12 month cycle, 12 month subscription

aPTT
PT (including INR)
TT
Fibrinogen
Antithrombin III

RQ9135/b (1 ml)
Full 16 Parameters + 1 pilot

D-dimer*
Factor II
Factor V
Factor VII
Factor VIII

Factor IX
Factor X
Factor XI
Factor XII
Plasminogen

Protein C
Protein S

CO-Oximetry Programme+

RQ9177 (1.2 ml)
First registered instrument
7 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription

Carboxyhaemoglobin (COHb / HbCO)
Deoxyhaemoglobin (HHb)

Methaemoglobin (MetHb)
Oxygen Content (O2CT)

Oxygen Saturation (sO2 / Vol O2)
Oxyhaemoglobin (O2Hb / HbO2)

Total Haemoglobin (tHb)

CYFRA 21-1 Programme+

RQ9175 (1 ml)
1 Parameter
Samples every month, 1 x 12 month cycle, 12 month subscription

CYFRA 21-1 (Cytokeratin 19)

Cytokines Programme+

RQ9195 (1 ml)
1 Parameter + 11 pilots
Samples every month, 1 x 12 month cycle, 12 month subscription

Epidermal Growth Factor (EGF)*
Interleukin – 1 alpha (IL-1α)*
Interleukin – 1 beta (IL-1β)*
Interleukin – 2 (IL-2)*

Interleukin – 4 (IL-4)*
Interleukin – 6 (IL-6)
Interleukin – 8 (IL-8)*
Interleukin – 10 (IL-10)*

Interferon gamma (INF-γ)*
Monocyte Chemoattractant Protein -1 (MCP-1)*
Tumour Necrosis Factor alpha (TNF-α)*

Vascular Endothelial Growth Factor (VEGF)*

ESR Programme+

RQ9163 (4.5 ml)
1 Parameter
2 samples per quarterly distribution, 1 x 12 month cycle, 12 month subscription

ESR (Erythrocyte Sedimentation Rate)

General Clinical Chemistry Programme *With target scoring*

RQ9112/a (5 ml)
10 Parameters

RQ9112/b (5 ml)
17 Parameters

RQ9112/c (5 ml)
Full 56 Parameters

RQ9128 (5ml)
Full 56 Parameters

Samples every 2 weeks, 2 x 6 monthly cycles, 12 month subscription, reference method values

Samples every month, 1 x 12 monthly cycle, 12 month subscription

ACE (Angiotensin Converting Enzyme)
Acid Phosphatase (Prostatic)
Acid Phosphatase (Total)
Albumin
Alkaline Phosphatase
ALT (ALAT)
Amylase (Pancreatic)
Amylase (Total)
AST (ASAT)
Bicarbonate
Bile Acids
Bilirubin (Direct)
Bilirubin (Total)
Calcium

Calcium, Adjusted
Calcium (Ionised)
Chloride
Cholesterol
Cholinesterase
CK, Total (CPK)
Copper
Creatinine
D-3-Hydroxybutyrate
eGFR (estimated glomerular filtration rate)
Fructosamine
γGT
GLDH
Glucose

HBDH
HDL-Cholesterol
Iron
Lactate
LD (LDH)
LDL-Cholesterol
Lipase
Lithium
Magnesium
NEFA
Non-HDL Cholesterol
Osmolality
Phosphate (Inorganic)
Potassium

Protein (Total)
PSA
Sodium
TIBC
T₃ (Free)
T₃ (Total)
T₄ (Free)
T₄ (Total)
Triglycerides
TSH
UIBC
Urea
Uric Acid
Zinc

Glycated Haemoglobin Programme (HbA1c) *With target scoring*

RQ9129 (0.5ml)
2 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription

HbA1c

Total Haemoglobin

 = Liquid ready-to-use samples

 = Lyophilised samples

PURPLE = The only parameters available on RQ9135/a

+ = Not accredited

* = Pilot study ongoing

Haematology Programme *With target scoring*

RQ9118 (2 ml)
11 Parameters

Samples every 2 weeks, 2 x 6 monthly cycles, 12 month subscription

Haematocrit (HCT)
Haemoglobin (Hb)
Mean Cell Haemoglobin (MCH)

Mean Cell Haemoglobin Concentration (MCHC)
Mean Cell Volume (MCV)

RQ9140 (2ml)
11 Parameters

Samples every month, 1 x 12 monthly cycle, 12 month subscription

Mean Platelet Volume (MPV)
Platelets (PLT)
Plateletcrit (PCT)

Red Blood Cell Count (RBC)
Red Cell Distribution Width (RDW)
Total White Blood Cell Count (WBC)

Human Urine Programme *With target scoring*

RQ9115 (2 x 10 ml)
25 Parameters

Samples every 2 weeks, 2 x 6 monthly cycles, 12 month subscription

ACR
Albumin/Microalbumin
Amylase
Calcium
Chloride
Copper
Cortisol

Creatinine
Dopamine
Epinephrine
Glucose
Metanephrine
Norepinephrine

RQ9185 (10ml)
25 Parameters

Samples every month, 1 x 12 monthly cycle, 12 month subscription

Normetanephrine
Magnesium
Osmolality
Oxalate
Phosphate (Inorganic)
Potassium

Protein (Total)
Sodium
Urea
Uric Acid
VMA
5-HIAA

Immunoassay Programme *With target scoring*

RQ9125/a (5 ml)

4 Parameters only + 2 pilots

Samples every two weeks, 2 x 6 monthly cycles, 12 month subscription (RQ9125/a, RQ9125/b, RQ9125/c)

ACTH
AFP
Aldosterone
Amikacin
Androstenedione
β-2-Microglobulin
CA125
CA15-3
CA19-9
Carbamazepine
CEA
Cortisol
C-Peptide

RQ9125/b (5 ml)

13 Parameters only + 2 pilots

DHEA-Sulphate
DHEA Unconjugated
Digoxin
Ferritin
Folate
FSH
Gentamicin
GH
hCG
IgE
Insulin
LH
Oestradiol

RQ9125/c (5 ml)

Full 49 Parameters + 2 pilots

17-OH-Progesterone
Paracetamol
Phenobarbital
Phenytoin
Progesterone
Prolactin
PSA (Free)
PSA (Total)
PTH
Salicylate
SHBG
T₃ (Free)
T₃ (Total)

RQ9130 (5 ml)

Full 49 Parameters + 2 pilots
Samples every month, 1 x 12 month cycle, 12 month subscription RQ9130)

T₄ (Free)
T₄ (Total)
Testosterone (Free)*
Testosterone (Total)
Theophylline
Thyroglobulin
TSH
Valproic Acid
Vancomycin
Vitamin B12
1-25-(OH)₂-Vitamin D*
25-OH-Vitamin D

Immunoassay Speciality 1 Programme *With target scoring*

RQ9141 (2 ml)

9 Parameters + 1 pilot

Samples every month, 1 x 12 month cycle, 12 month subscription

1-25-(OH)₂-Vitamin D*
25-OH-Vitamin D
C-Peptide

Anti-TG
Anti-TPO
IGF-1

Osteocalcin
Procalcitonin
PTH

Insulin

Immunoassay Speciality 2 Programme *With target scoring*

RQ9142 (1 ml)

5 Parameters

Samples every month, 1 x 12 month cycle, 12 month subscription

Calcitonin
Gastrin

Procalcitonin

Plasma Renin Activity

Renin (Direct Concentration)

Immunosuppressant Programme+

RQ9159 (2 ml)

4 Parameters

Samples every month, 1 x 12 month cycle, 12 month subscription, reference method values

Ciclosporin

Everolimus

Sirolimus

Tacrolimus

Lipid Programme *With target scoring*

RQ9126/a (3 ml)

3 Parameters only (choose from 7)

Samples every 2 weeks, 2 x 6 monthly cycles, 12 month subscription

Apolipoprotein A1
Apolipoprotein B

Cholesterol (Total)
HDL-Cholesterol

LDL-Cholesterol
Lipoprotein (a)

Triglycerides

 = Liquid ready-to-use samples

 = Lyophilised samples

PURPLE = The only parameters available on RQ9135/a

+ = Not accredited

* = Pilot study ongoing

RIQAS PROGRAMMES

Maternal Screening Programme *With target scoring*

RQ9137 (1 ml)
6 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription

AFP
 free β -hCG

Total hCG
 Inhibin A

PAPP-A

Unconjugated Oestriol

Microbiology (Bacterial Identification) Programme+

RQ9197
1 strain (complete with case study)
Samples every 2 months, 1 x 12 month cycles, 12 month subscription

1 strain complete with case study. Identification of the micro-organisms can be made at Gram positive / negative, Genus and Species level. Antimicrobial Susceptibility Testing on identified strain

Antimicrobial Susceptibility Testing

Strain Identification

Neonatal Bilirubin Programme+

RQ9191 (3 ml)
2 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription

Direct Bilirubin

Total Bilirubin

Serology (EBV) Programme+

RQ9153 (1 ml)
3 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription, Quantitative and Qualitative results

Anti-EBV VCA IgG

Anti-EBNA IgG

Anti-EBV VCA IgM

Serology (HIV-Hepatitis) Programme+

RQ9151 (1.8 ml)
10 Parameters + 6 pilots
Samples every month, 1 x 12 month cycle, 12 month subscription, Quantitative and Qualitative results

Anti-CMV (Total)
 Anti-HAV IgM*
 Anti-HAV (Total)*
 Anti-HBc

Anti-HBc IgM*
 Anti-HBe (Total)*
 Anti-HBs (Total)*
 Anti-HCV

Anti-HIV-1
 Anti-HIV-2
 Anti-HIV combined
 Anti-HTLV I

Anti-HTLV II
 Anti-HTLV combined
 HBsAg
 P24*

Serology (Syphilis) Programme+

RQ9154 (1 ml)
1 Parameter
Samples every month, 1 x 12 month cycle, 12 month subscription, Quantitative and Qualitative results

Syphilis (Methods available include immunoassay RPR, VDRL and TPHA)

Serology (ToRCH) Programme+

RQ9152 (1 ml)
12 Parameters + 3 pilots
Samples every month, 1 x 12 month cycle, 12 month subscription, Quantitative and Qualitative results

Anti-CMV IgG
 Anti-CMV IgM
 Anti-HSV1 IgG
 Anti-HSV1 IgM

Anti-HSV2 IgG
 Anti-HSV2 IgM
 Anti-HSV1/2 IgG
 Anti-HSV1/2 IgM

Anti-Measles IgG*
 Anti-Mumps IgG*
 Anti-Rubella IgG
 Anti-Rubella IgM

Anti-Toxoplasma IgG
 Anti-Toxoplasma IgM
 Anti-VZV IgG*

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

| # | Ammonia / Ethanol | Anti-Mullerian Hormone (AMH) + | Anti-TSH Receptor + | Blood Gas | BNP + | Cardiac | Cardiac Plus | Cerebrospinal Fluid + | Coagulation | CO-Oximetry + | CYFRA 21-1 + | Cytokines + | ESR + | General Clinical Chemistry | HbA1c | Haematology | Human Urine | Immunoassay |
|---|--------------------------------------|--------------------------------|---------------------|-----------|-------|---------|--------------|-----------------------|-------------|---------------|--------------|-------------|-------|----------------------------|-------|-------------|-------------|-------------|
| | 1-25-(OH) ₂ -Vitamin D* | | | | | | | | | | | | | | | | | X |
| | 17-OH-Progesterone | | | | | | | | | | | | | | | | | X |
| | 25-OH-Vitamin D | | | | | | | | | | | | | | | | | X |
| | 5-HIAA | | | | | | | | | | | | | | | | X | |
| A | α-1-Acid Glycoprotein | | | | | | | | | | | | | | | | | |
| | α-1-Antitrypsin | | | | | | | | | | | | | | | | | |
| | α-2-Macroglobulin | | | | | | | | | | | | | | | | | |
| | ACE (Angiotensin Converting Enzyme) | | | | | | | | | | | | | X | | | | |
| | Acid Phosphatase (Prostatic) | | | | | | | | | | | | | X | | | | |
| | Acid Phosphatase (Total) | | | | | | | | | | | | | X | | | | |
| | ACR | | | | | | | | | | | | | | | | X | |
| | ACTH | | | | | | | | | | | | | | | | | X |
| | AFP | | | | | | | | | | | | | | | | | X |
| | Albumin | | | | | | | X | | | | | | X | | X | | |
| | Aldosterone | | | | | | | | | | | | | | | | | X |
| | Alkaline Phosphatase | | | | | | | | | | | | | X | | | | |
| | ALT | | | | | | | | | | | | | X | | | | |
| | ALT (ALAT) | | | | | | | | | | | | | X | | | | |
| | Amikacin | | | | | | | | | | | | | | | | | X |
| | Ammonia | X | | | | | | | | | | | | | | | | |
| | Amylase (Pancreatic) | | | | | | | | | | | | | X | | | | |
| | Amylase (Total) | | | | | | | | | | | | | X | | X | | |
| | Androstenedione | | | | | | | | | | | | | | | | | X |
| | Anti Streptolysin O (ASO) | | | | | | | | | | | | | | | | | |
| | Anti-CMV | | | | | | | | | | | | | | | | | |
| | Anti-CMV IgG | | | | | | | | | | | | | | | | | |
| | Anti-CMV IgM | | | | | | | | | | | | | | | | | |
| | Anti-EBNA IgG | | | | | | | | | | | | | | | | | |
| | Anti-EBV VCA IgG | | | | | | | | | | | | | | | | | |
| | Anti-EBV VCA IgM | | | | | | | | | | | | | | | | | |
| | Anti-HAV IgM* | | | | | | | | | | | | | | | | | |
| | Anti-HAV (Total)* | | | | | | | | | | | | | | | | | |
| | Anti-HBc | | | | | | | | | | | | | | | | | |
| | Anti-HBc IgM* | | | | | | | | | | | | | | | | | |
| | Anti-HBe (Total)* | | | | | | | | | | | | | | | | | |
| | Anti-HBs (Total)* | | | | | | | | | | | | | | | | | |
| | Anti-HCV | | | | | | | | | | | | | | | | | |
| | Anti-HIV-1 | | | | | | | | | | | | | | | | | |
| | Anti-HIV-1 & 2 Combined | | | | | | | | | | | | | | | | | |
| | Anti-HIV-2 | | | | | | | | | | | | | | | | | |
| | Anti-HSV-1 & 2 IgG Combined | | | | | | | | | | | | | | | | | |
| | Anti-HSV-1 & 2 IgM Combined | | | | | | | | | | | | | | | | | |
| | Anti-HSV1 IgG | | | | | | | | | | | | | | | | | |
| | Anti-HSV1 IgM | | | | | | | | | | | | | | | | | |
| | Anti-HSV2 IgG | | | | | | | | | | | | | | | | | |
| | Anti-HSV2 IgM | | | | | | | | | | | | | | | | | |
| | Anti-HTLV-1 & 2 Combined | | | | | | | | | | | | | | | | | |
| | Anti-HTLV-I | | | | | | | | | | | | | | | | | |
| | Anti-HTLV-II | | | | | | | | | | | | | | | | | |
| | Anti-Measles IgG* | | | | | | | | | | | | | | | | | |
| | Antimicrobial Susceptibility Testing | | | | | | | | | | | | | | | | | |

^a Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

| Immunoassay Speciality 1 | Immunoassay Speciality 2 | Immunosuppressant + | Lipid | Maternal Screening | Microbiology (Bacterial Identification) + | Neonatal Bilirubin + | Serology (EBV) + | Serology (HIV / Hepatitis) + | Serology (Syphilis) + | Serology (ToRCH) + | Serum Indices + | Specific Proteins | Sweat Testing + | Therapeutic Drug | Urinalysis | Urine Toxicology + | | |
|--------------------------|--------------------------|---------------------|-------|--------------------|---|----------------------|------------------|------------------------------|-----------------------|--------------------|-----------------|-------------------|-----------------|------------------|------------|--------------------|--------------------------------------|---|
| X | | | | | | | | | | | | | | | | | 1-25-(OH) ₂ -Vitamin D* | # |
| | | | | | | | | | | | | | | | | | 17-OH-Progesterone | |
| X | | | | | | | | | | | | | | | | | 25-OH-Vitamin D | |
| | | | | | | | | | | | | | | | | | 5-HIAA | |
| | | | | | | | | | | | | X | | | | | α-1-Acid Glycoprotein | A |
| | | | | | | | | | | | | X | | | | | α-1-Antitrypsin | |
| | | | | | | | | | | | | X | | | | | α-2-Macroglobulin | |
| | | | | | | | | | | | | | | | | | ACE (Angiotensin Converting Enzyme) | |
| | | | | | | | | | | | | | | | | | Acid Phosphatase (Prostatic) | |
| | | | | | | | | | | | | | | | | | Acid Phosphatase (Total) | |
| | | | | | | | | | | | | | | | | | ACR | |
| | | | | | | | | | | | | | | | | | ACTH | |
| | | | | X | | | | | | | | X | | | | | AFP | |
| | | | | | | | | | | | | X | | | X | | Albumin | |
| | | | | | | | | | | | | | | | | | Aldosterone | |
| | | | | | | | | | | | X | | | | | | Alkaline Phosphatase | |
| | | | | | | | | | | | X | | | | | | ALT | |
| | | | | | | | | | | | | | | | | | ALT (ALAT) | |
| | | | | | | | | | | | | | | X | | | Amikacin | |
| | | | | | | | | | | | | | | | | | Ammonia | |
| | | | | | | | | | | | | | | | | | Amylase (Pancreatic) | |
| | | | | | | | | | | | | | | | | | Amylase (Total) | |
| | | | | | | | | | | | | X | | | | | Androstenedione | |
| | | | | | | | | | | | | X | | | | | Anti Streptolysin O (ASO) | |
| | | | | | | | | X | | | | | | | | | Anti-CMV | |
| | | | | | | | | | X | | | | | | | | Anti-CMV IgG | |
| | | | | | | | | | X | | | | | | | | Anti-CMV IgM | |
| | | | | | | X | | | | | | | | | | | Anti-EBNA IgG | |
| | | | | | | X | | | | | | | | | | | Anti-EBV VCA IgG | |
| | | | | | | X | | | | | | | | | | | Anti-EBV VCA IgM | |
| | | | | | | | X | | | | | | | | | | Anti-HAV IgM* | |
| | | | | | | | X | | | | | | | | | | Anti-HAV (Total)* | |
| | | | | | | | X | | | | | | | | | | Anti-HBc | |
| | | | | | | | X | | | | | | | | | | Anti-HBc IgM* | |
| | | | | | | | X | | | | | | | | | | Anti-HBe (Total)* | |
| | | | | | | | X | | | | | | | | | | Anti-HBs (Total)* | |
| | | | | | | | X | | | | | | | | | | Anti-HCV | |
| | | | | | | | X | | | | | | | | | | Anti-HIV-1 | |
| | | | | | | | X | | | | | | | | | | Anti-HIV-1 & 2 Combined | |
| | | | | | | | X | | | | | | | | | | Anti-HIV-2 | |
| | | | | | | | | X | | | | | | | | | Anti-HSV-1 & 2 IgG Combined | |
| | | | | | | | | | X | | | | | | | | Anti-HSV-1 & 2 IgM Combined | |
| | | | | | | | | | X | | | | | | | | Anti-HSV1 IgG | |
| | | | | | | | | | X | | | | | | | | Anti-HSV1 IgM | |
| | | | | | | | | | X | | | | | | | | Anti-HSV2 IgG | |
| | | | | | | | | | X | | | | | | | | Anti-HSV2 IgM | |
| | | | | | | | X | | | | | | | | | | Anti-HTLV-1 & 2 Combined | |
| | | | | | | | X | | | | | | | | | | Anti-HTLV-I | |
| | | | | | | | X | | | | | | | | | | Anti-HTLV-II | |
| | | | | | | | | X | | | | | | | | | Anti-Measles IgG* | |
| | | | | X | | | | | | X | | | | | | | Antimicrobial Susceptibility Testing | |

⁴ Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

| | | Ammonia / Ethanol | Anti-Mullerian Hormone (AMH) + | Anti-TSH Receptor + | Blood Gas | BNP + | Cardiac | Cardiac Plus | Cerebrospinal Fluid + | Coagulation | CO-Oximetry + | CYFRA 21-1 + | Cytokines + | ESR + | General Clinical Chemistry | HbA1c | Haematology | Human Urine | Immunoassay |
|--------------------|----------------------------------|-------------------|--------------------------------|---------------------|-----------|-------|---------|--------------|-----------------------|-------------|---------------|--------------|-------------|-------|----------------------------|-------|-------------|-------------|-------------|
| A | Anti-Müllerian Hormone (AMH) | | X | | | | | | | | | | | | | | | | |
| | Anti-Mumps IgG* | | | | | | | | | | | | | | | | | | |
| | Anti-Rubella IgG | | | | | | | | | | | | | | | | | | |
| | Anti-Rubella IgM | | | | | | | | | | | | | | | | | | |
| | Anti-TG | | | | | | | | | | | | | | | | | | |
| | Antithrombin III | | | | | | | | | X | | | | | | | | | |
| | Anti-Toxoplasma IgG | | | | | | | | | | | | | | | | | | |
| | Anti-Toxoplasma IgM | | | | | | | | | | | | | | | | | | |
| | Anti-TPO | | | | | | | | | | | | | | | | | | |
| | Anti-TSH Receptor (TRAb) | | | X | | | | | | | | | | | | | | | |
| | Anti-VZV IgG* | | | | | | | | | | | | | | | | | | |
| | Apolipoprotein AI | | | | | | | | | | | | | | | | | | |
| | Apolipoprotein B | | | | | | | | | | | | | | | | | | |
| | aPTT | | | | | | | | | | X | | | | | | | | |
| | AST | | | | | | | | | | | | | | | | | | |
| | AST (ASAT) | | | | | | | | | | | | | | | X | | | |
| | B | β-2-Microglobulin | | | | | | | | | | | | | | | | | |
| Benzoylecgonine | | | | | | | | | | | | | | | | | | | |
| Bicarbonate | | | | | X | | | | | | | | | | X | | | | |
| Bile Acids | | | | | | | | | | | | | | | X | | | | |
| Bilirubin (Direct) | | | | | | | | | | | | | | | X | | | | |
| Bilirubin (Total) | | | | | | | | | | | | | | | X | | | | |
| Blood | | | | | | | | | | | | | | | | | | | |
| BNP | | | | | | X | | | | | | | | | | | | | |
| Buprenorphine | | | | | | | | | | | | | | | | | | | |
| C | CA15-3 | | | | | | | | | | | | | | | | | | X |
| | CA19-9 | | | | | | | | | | | | | | | | | | X |
| | CA125 | | | | | | | | | | | | | | | | | | X |
| | Caffeine | | | | | | | | | | | | | | | | | | |
| | Calcitonin | | | | | | | | | | | | | | | | | | |
| | Calcium | | | | | | | | | | | | | | X | | | X | |
| | Calcium, Adjusted | | | | | | | | | | | | | | X | | | | |
| | Calcium (Ionised) | | | | X | | | | | | | | | | X | | | | |
| | Cannabinoids (THC) | | | | | | | | | | | | | | | | | | |
| | Carbamazepine | | | | | | | | | | | | | | | | | | X |
| | Carboxyhaemoglobin (COHb / HbCO) | | | | | | | | | | X | | | | | | | | |
| | CEA | | | | | | | | | | | | | | | | | | X |
| | Ceruloplasmin | | | | | | | | | | | | | | | | | | |
| | Chloride | | | | X | | | | X | | | | | | X | | | X | |
| | Cholesterol (Total) | | | | | | | | | | | | | | | X | | | |
| | Cholinesterase | | | | | | | | | | | | | | | X | | | |
| | Ciclosporin | | | | | | | | | | | | | | | | | | |
| | CK, Total | | | | | | | X | X | | | | | | | X | | | |
| | CK-MB (Activity) | | | | | | | X | X | | | | | | | | | | |
| | CK-MB (Mass) | | | | | | | X | X | | | | | | | | | | |
| | CK NAC | | | | | | | | | | | | | | | | | | |
| | CO2, Total | | | | | X | | | | | | | | | | | | | |
| | Complement C ₃ | | | | | | | | | | | | | | | | | | |
| C | Complement C ₄ | | | | | | | | | | | | | | | | | | |
| | Conductivity | | | | | | | | | | | | | | | | | | |
| | Copper | | | | | | | | | | | | | | X | | | X | |

^a Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

| Immunosassay Speciality 1 | Immunosassay Speciality 2 | Immunosuppressant + | Lipid | Maternal Screening | Microbiology (Bacterial Identification) + | Neonatal Bilirubin + | Serology (EBV) + | Serology (HIV / Hepatitis) + | Serology (Syphilis) + | Serology (ToRCH) + | Serum Indices + | Specific Proteins | Sweat Testing + | Therapeutic Drug | Urinalysis | Urine Toxicology + | | |
|---------------------------|---------------------------|---------------------|-------|--------------------|---|----------------------|------------------|------------------------------|-----------------------|--------------------|-----------------|-------------------|-----------------|------------------|------------|--------------------|----------------------------------|---|
| | | | | | | | | | | | | | | | | | Anti-Müllerian Hormone (AMH) | A |
| | | | | | | | | | | X | | | | | | | Anti-Mumps IgG* | |
| | | | | | | | | | | X | | | | | | | Anti-Rubella IgG | |
| | | | | | | | | | | X | | | | | | | Anti-Rubella IgM | |
| X | | | | | | | | | | | | | | | | | Anti-TG | |
| | | | | | | | | | | | | X | | | | | Antithrombin III | |
| | | | | | | | | | | X | | | | | | | Anti-Toxoplasma IgG | |
| | | | | | | | | | | X | | | | | | | Anti-Toxoplasma IgM | |
| X | | | | | | | | | | | | | | | | | Anti-TPO | |
| | | | | | | | | | | | | | | | | | Anti-TSH Receptor (TRAb) | |
| | | | | | | | | | | X | | | | | | | Anti-VZV IgG* | |
| | | | X | | | | | | | | | | | | | | Apolipoprotein AI | |
| | | | X | | | | | | | | | | | | | | Apolipoprotein B | |
| | | | | | | | | | | | | | | | | | aPTT | |
| | | | | | | | | | | | X | | | | | | AST | |
| | | | | | | | | | | | | | | | | | AST (ASAT) | |
| | | | | | | | | | | | | X | | | | | β-2-Microglobulin | B |
| | | | | | | | | | | | | | | | | X | Benzoylcegonine | |
| | | | | | | | | | | | | | | | | | Bicarbonate | |
| | | | | | | | | | | | | | | | | | Bile Acids | |
| | | | | | | X | | | | | X | | | | | | Bilirubin (Direct) | |
| | | | | | X | | | | | | X | | | | | | Bilirubin (Total) | |
| | | | | | | | | | | | | | | | | X | Blood | |
| | | | | | | | | | | | | | | | | | BNP | |
| | | | | | | | | | | | | | | | | X | Buprenorphine | |
| | | | | | | | | | | | | | | | | | CA15-3 | C |
| | | | | | | | | | | | | | | | | | CA19-9 | |
| | | | | | | | | | | | | | | | | | CA125 | |
| | X | | | | | | | | | | | | | X | | | Caffeine | |
| | | | | | | | | | | | X | | | | | | Calcitonin | |
| | | | | | | | | | | | | | | | | | Calcium | |
| | | | | | | | | | | | | | | | | | Calcium, Adjusted | |
| | | | | | | | | | | | | | | | | | Calcium (Ionised) | |
| | | | | | | | | | | | | | | | | X | Cannabinoids (THC) | |
| | | | | | | | | | | | | | | X | | | Carbamazepine | |
| | | | | | | | | | | | | | | | | | Carboxyhaemoglobin (COHb / HbCO) | |
| | | | | | | | | | | | | | | | | | CEA | |
| | | | | | | | | | | | | X | | | | | Ceruloplasmin | |
| | | | | | | | | | | | X | | X | | | | Chloride | |
| | | | X | | | | | | | | X | | | | | | Cholesterol (Total) | |
| | | X | | | | | | | | | | | | | | | Cholinesterase | |
| | | | | | | | | | | | | | | X | | | Ciclosporin | |
| | | | | | | | | | | | | | | | | | CK, Total | |
| | | | | | | | | | | | | | | | | | CK-MB (Activity) | |
| | | | | | | | | | | | | | | | | | CK-MB (Mass) | |
| | | | | | | | | | | | X | | | | | | CK NAC | |
| | | | | | | | | | | | | | | | | | CO2, Total | |
| | | | | | | | | | | | | X | | | | | Complement C ₃ | |
| | | | | | | | | | | | | X | | | | | Complement C ₄ | C |
| | | | | | | | | | | | | | X | | | | Conductivity | |
| | | | | | | | | | | | | | | | | | Copper | |

⁴ Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

| | | Ammonia / Ethanol | Anti-Mullerian Hormone (AMH) + | Anti-TSH Receptor + | Blood Gas | BNP + | Cardiac | Cardiac Plus | Cerebrospinal Fluid + | Coagulation | CO-Oximetry + | CYFRA 21-1 + | Cytokines + | ESR + | General Clinical Chemistry | HbA1c | Haematology | Human Urine | Immunoassay |
|---|-----------------------------|-------------------|--------------------------------|---------------------|-----------|-------|---------|--------------|-----------------------|-------------|---------------|--------------|-------------|-------|----------------------------|-------|-------------|-------------|-------------|
| C | Cortisol | | | | | | | | | | | | | | | | | X | X |
| | Cotinine | | | | | | | | | | | | | | | | | | |
| | C-Peptide | | | | | | | | | | | | | | | | | | X |
| | C-Reactive Protein (CRP) | | | | | | | | | | | | | | | | | | |
| | Creatinine | | | | | | | | | | | | | | X | | | X | |
| | CYFRA 21-1 (Cytokeratin 19) | | | | | | | | | | | X | | | | | | | |
| D | D-3-Hydroxybutyrate | | | | | | | | | | | | | | X | | | | |
| | d-Amphetamine | | | | | | | | | | | | | | | | | | |
| | D-Dimer* ^Δ | | | | | | | X | | X | | | | | | | | | |
| | Deoxyhaemoglobin (HHb) | | | | | | | | | | X | | | | | | | | |
| | DHEA Unconjugated | | | | | | | | | | | | | | | | | | X |
| | DHEA-Sulphate | | | | | | | | | | | | | | | | | | X |
| | Digoxin | | | | | | | X | | | | | | | | | | | X |
| | d-Methamphetamine | | | | | | | | | | | | | | | | | | |
| | Dopamine | | | | | | | | | | | | | | | | | X | |
| | E | EDDP | | | | | | | | | | | | | | | | | |
| eGFR (estimated glomerular filtration rate) | | | | | | | | | | | | | | | X | | | | |
| Epidermal Growth Factor (EGF)* | | | | | | | | | | | | | X | | | | | | |
| Epinephrine | | | | | | | | | | | | | | | | | | X | |
| ESR | | | | | | | | | | | | | | X | | | | | |
| Ethanol | | X | | | | | | | | | | | | | | | | | |
| Ethosuximide | | | | | | | | | | | | | | | | | | | |
| F | Factor II | | | | | | | | | X | | | | | | | | | |
| | Factor IX | | | | | | | | | X | | | | | | | | | |
| | Factor V | | | | | | | | | X | | | | | | | | | |
| | Factor VII | | | | | | | | | X | | | | | | | | | |
| | Factor VIII | | | | | | | | | X | | | | | | | | | |
| | Factor X | | | | | | | | | X | | | | | | | | | |
| | Factor XI | | | | | | | | | X | | | | | | | | | |
| | Factor XII | | | | | | | | | X | | | | | | | | | |
| | Ferritin | | | | | | | | | | | | | | | | | | X |
| | Fibrinogen | | | | | | | | | X | | | | | | | | | |
| | Folate | | | | | | | | | | | | | | | | | | X |
| | Free Morphine | | | | | | | | | | | | | | | | | | |
| | free β-hCG | | | | | | | | | | | | | | | | | | |
| | Fructosamine | | | | | | | | | | | | | | X | | | | |
| | FSH | | | | | | | | | | | | | | | | | | X |
| | G | γ-GT | | | | | | | | | | | | | | X | | | |
| Galactose | | | | | | | | | | | | | | | | | | | |
| Gastrin | | | | | | | | | | | | | | | | | | | |
| Gentamicin | | | | | | | | | | | | | | | | | | | X |
| Growth Hormone (GH) | | | | | | | | | | | | | | | | | | | X |
| GLDH | | | | | | | | | | | | | | | X | | | | |
| Glucose | | | | | X | | | X | | | | | | | X | | | X | |
| H | Haematocrit (HCT) | | | | | | | | | | | | | | | | X | | |
| | Haemoglobin (Hb) | | | | | | | | | | | | | | | | X | | |
| | Total Haemoglobin (tHb) | | | | | | | | | X | | | | | X | | | | |
| | Haemolysis | | | | | | | | | | | | | | | | | | |
| | Haptoglobin | | | | | | | | | | | | | | | | | | |
| | HbA1c | | | | | | | | | | | | | | X | | | | |

^Δ Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

| Immunoassay Speciality 1 | Immunoassay Speciality 2 | Immunosuppressant + | Lipid | Maternal Screening | Microbiology (Bacterial Identification) + | Neonatal Bilirubin + | Serology (EBV) + | Serology (HIV / Hepatitis) + | Serology (Syphilis) + | Serology (ToRCH) + | Serum Indices + | Specific Proteins | Sweat Testing + | Therapeutic Drug | Urinalysis | Urine Toxicology + | | | |
|--------------------------|--------------------------|---------------------|-------|--------------------|---|----------------------|------------------|------------------------------|-----------------------|--------------------|-----------------|-------------------|-----------------|------------------|------------|--------------------|-----------------------------|---|------------------------|
| | | | | | | | | | | | | | | | | | Cortisol | C | |
| | | | | | | | | | | | | | | | | X | Cotinine | | |
| X | | | | | | | | | | | | | | | | | C-Peptide | | |
| | | | | | | | | | | | | X | | | | | C-Reactive Protein (CRP) | D | |
| | | | | | | | | | | | X | | | | X | X | Creatinine | | |
| | | | | | | | | | | | | | | | | | CYFRA 21-1 (Cytokeratin 19) | | |
| | | | | | | | | | | | | | | | | | D-3-Hydroxybutyrate | | |
| | | | | | | | | | | | | | | | | | X | | d-Amphetamine |
| | | | | | | | | | | | | | | | | | | | D-Dimer* ^Δ |
| | | | | | | | | | | | | | | | | | | | Deoxyhaemoglobin (HHb) |
| | | | | | | | | | | | | | | | | | | | DHEA Unconjugated |
| | | | | | | | | | | | | | | | | | | | DHEA-Sulphate |
| | | | | | | | | | | | | | | | X | | | | Digoxin |
| | | | | | | | | | | | | | | | | | X | d-Methamphetamine | |
| | | | | | | | | | | | | | | | | | | Dopamine | |
| | | | | | | | | | | | | | | | | | X | EDDP | |
| | | | | | | | | | | | | | | | | | | eGFR (estimated glomerular filtration rate) | |
| | | | | | | | | | | | | | | | | | | Epidermal Growth Factor (EGF)* | |
| | | | | | | | | | | | | | | | | | | Epinephrine | |
| | | | | | | | | | | | | | | | | | | ESR | |
| | | | | | | | | | | | | | | | | | X | Ethanol | |
| | | X | | | | | | | | | | | | | X | | | Ethosuximide | |
| | | | | | | | | | | | | | | | | | | Everolimus | |
| | | | | | | | | | | | | | | | | | | Factor II | |
| | | | | | | | | | | | | | | | | | | Factor IX | |
| | | | | | | | | | | | | | | | | | | Factor V | |
| | | | | | | | | | | | | | | | | | | Factor VII | |
| | | | | | | | | | | | | | | | | | | Factor VIII | |
| | | | | | | | | | | | | | | | | | | Factor X | |
| | | | | | | | | | | | | | | | | | | Factor XI | |
| | | | | | | | | | | | | | | | | | | Factor XII | |
| | | | | | | | | | | | | X | | | | | | Ferritin | |
| | | | | | | | | | | | | | | | | | | Fibrinogen | |
| | | | | | | | | | | | | | | | | | | Folate | |
| | | | | | | | | | | | | | | | | X | | Free Morphine | |
| | | | | X | | | | | | | | | | | | | | free β-hCG | |
| | | | | | | | | | | | | | | | | | | Fructosamine | |
| | | | | | | | | | | | | | | | | | | FSH | |
| | | | | | | | | | | | X | | | | | | | γ-GT | |
| | X | | | | | | | | | | | | | | | X | | Galactose | |
| | | | | | | | | | | | | | | | | | | Gastrin | |
| | | | | | | | | | | | | | | X | | | | Gentamicin | |
| | | | | | | | | | | | | | | | | | | Growth Hormone (GH) | |
| | | | | | | | | | | | | | | | | | | GLDH | |
| | | | | | | | | | | | X | | | | X | | | Glucose | |
| | | | | | | | | | | | | | | | | | | Haematocrit (HCT) | |
| | | | | | | | | | | | | | | | | | | Haemoglobin (Hb) | |
| | | | | | | | | | | | | | | | | | | Total Haemoglobin (tHb) | |
| | | | | | | | | | | | X | | | | | | | Haemolysis | |
| | | | | | | | | | | | | X | | | | | | Haptoglobin | |
| | | | | | | | | | | | | | | | | | | HbA1c | |

^Δ Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

| | | Ammonia / Ethanol | Anti-Mullerian Hormone (AMH) + | Anti-TSH Receptor + | Blood Gas | BNP + | Cardiac | Cardiac Plus | Cerebrospinal Fluid + | Coagulation | CO-Oximetry + | CYFRA 21-1 + | Cytokines + | ESR + | General Clinical Chemistry | HbA1c | Haematology | Human Urine | Immunoassay |
|------|---|-------------------|--------------------------------|---------------------|-----------|-------|---------|--------------|-----------------------|-------------|---------------|--------------|-------------|-------|----------------------------|-------|-------------|-------------|-------------|
| H | HBsAg | | | | | | | | | | | | | | | | | | |
| | HBDH | | | | | | | | | | | | | | X | | | | |
| | hCG | | | | | | | | | | | | | | | | | | X |
| | HDL-Cholesterol | | | | | | | | | | | | | | X | | | | |
| | Homocysteine | | | | | | X | X | | | | | | | | | | | |
| | hsCRP | | | | | | | X | | | | | | | | | | | |
| I | Icteric | | | | | | | | | | | | | | | | | | |
| | IgA | | | | | | | | | | | | | | | | | | |
| | IgE | | | | | | | | | | | | | | | | | | X |
| | IGF-1 | | | | | | | | | | | | | | | | | | |
| | IgG | | | | | | | | X | | | | | | | | | | |
| | IgM | | | | | | | | | | | | | | | | | | |
| | Inhibin A | | | | | | | | | | | | | | | | | | |
| | Insulin | | | | | | | | | | | | | | | | | | X |
| | Interferon gamma (INF- γ)* | | | | | | | | | | | | X | | | | | | |
| | Interleukin - 1 alpha (IL-1 α)* | | | | | | | | | | | | X | | | | | | |
| | Interleukin - 1 beta (IL-1 β)* | | | | | | | | | | | | X | | | | | | |
| | Interleukin - 10 (IL-10)* | | | | | | | | | | | | X | | | | | | |
| | Interleukin - 2 (IL-2)* | | | | | | | | | | | | X | | | | | | |
| | Interleukin - 4 (IL-4)* | | | | | | | | | | | | X | | | | | | |
| | Interleukin - 6 (IL-6) | | | | | | | | | | | | X | | | | | | |
| | Interleukin - 8 (IL-8)* | | | | | | | | | | | | X | | | | | | |
| Iron | | | | | | | | | | | | | | X | | | | | |
| K | Kappa Light Chain (Free) | | | | | | | | | | | | | | | | | | |
| | Kappa Light Chain (Total) | | | | | | | | | | | | | | | | | | |
| | Ketones | | | | | | | | | | | | | | | | | | |
| L | Lactate | | | | X | | | | X | | | | | | X | | | | |
| | Lambda Light Chain (Free) | | | | | | | | | | | | | | | | | | |
| | Lambda Light Chain (Total) | | | | | | | | | | | | | | | | | | |
| | LD (LDH) | | | | | | | | | | | | | | X | | | | |
| | LDL-Cholesterol | | | | | | | | | | | | | | X | | | | |
| | Leucocytes | | | | | | | | | | | | | | X | | | | |
| | Lipase | | | | | | | | | | | | | | X | | | | |
| | Lipoprotein (a) | | | | | | | | | | | | | | X | | | | |
| | Lithium | | | | | | | | | | | | | | X | | | | |
| | Lorazepam | | | | | | | | | | | | | | | | | | |
| | LSD | | | | | | | | | | | | | | | | | | |
| | Luteinising Hormone (LH) | | | | | | | | | | | | | | | | | | X |
| M | Magnesium | | | | | | | | | | | | | | X | | | X | |
| | MDMA | | | | | | | | | | | | | | | | | | |
| | Mean Cell Haemoglobin (MCH) | | | | | | | | | | | | | | | | X | | |
| | Mean Cell Haemoglobin Concentration (MCHC) | | | | | | | | | | | | | | | | X | | |
| | Mean Cell Volume (MCV) | | | | | | | | | | | | | | | | X | | |
| | Mean Platelet Volume (MPV) | | | | | | | | | | | | | | | | X | | |
| | Metanephrine | | | | | | | | | | | | | | | | | X | |
| | Methadone | | | | | | | | | | | | | | | | | | |
| | Methaemoglobin (MetHb) | | | | | | | | | | X | | | | | | | | |
| | Methotrexate | | | | | | | | | | | | | | | | | | |
| | Monocyte Chemoattractant Protein - 1 (MCP-1)* | | | | | | | | | | | | X | | | | | | |
| | Myoglobin | | | | | | X | X | | | | | | | | | | | |

^a Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

| Immunoassay Speciality 1 | Immunoassay Speciality 2 | Immunosuppressant + | Lipid | Maternal Screening | Microbiology (Bacterial Identification) + | Neonatal Bilirubin + | Serology (EBV) + | Serology (HIV / Hepatitis) + | Serology (Syphilis) + | Serology (ToRCH) + | Serum Indices + | Specific Proteins | Sweat Testing + | Therapeutic Drug | Urinalysis | Urine Toxicology + | | |
|--------------------------|--------------------------|---------------------|-------|--------------------|---|----------------------|------------------|------------------------------|-----------------------|--------------------|-----------------|-------------------|-----------------|------------------|------------|--------------------|--|---|
| | | | | | | | | X | | | | | | | | | HBsAg | H |
| | | | | | | | | | | | | | | | | | HBDH | |
| | | | | | | | | | | | | | | | X | | hCG | |
| | | | X | | | | | | | | X | | | | | | HDL-Cholesterol | |
| | | | | | | | | | | | | | | | | | Homocysteine | |
| | | | | | | | | | | | | | | | | | hsCRP | |
| | | | | | | | | | | | X | | | | | | Icteric | I |
| | | | | | | | | | | | | X | | | | | IgA | |
| | | | | | | | | | | | | X | | | | | IgE | |
| X | | | | | | | | | | | | | | | | | IGF-1 | |
| | | | | | | | | | | | | X | | | | | IgG | |
| | | | | | | | | | | | | X | | | | | IgM | |
| | | | | X | | | | | | | | | | | | | Inhibin A | |
| X | | | | | | | | | | | | | | | | | Insulin | |
| | | | | | | | | | | | | | | | | | Interferon gamma (INF- γ)* | |
| | | | | | | | | | | | | | | | | | Interleukin - 1 alpha (IL-1 α)* | |
| | | | | | | | | | | | | | | | | | Interleukin - 1 beta (IL-1 β)* | |
| | | | | | | | | | | | | | | | | | Interleukin - 10 (IL-10)* | |
| | | | | | | | | | | | | | | | | | Interleukin - 2 (IL-2)* | |
| | | | | | | | | | | | | | | | | | Interleukin - 4 (IL-4)* | |
| | | | | | | | | | | | | | | | | | Interleukin - 6 (IL-6) | |
| | | | | | | | | | | | | | | | | | Interleukin - 8 (IL-8)* | |
| | | | | | | | | | | | X | | | | | | Iron | |
| | | | | | | | | | | | | X | | | | | Kappa Light Chain (Free) | K |
| | | | | | | | | | | | | X | | | | | Kappa Light Chain (Total) | |
| | | | | | | | | | | | | | | | X | | Ketones | |
| | | | | | | | | | | | X | | | | | | Lactate | L |
| | | | | | | | | | | | | X | | | | | Lambda Light Chain (Free) | |
| | | | | | | | | | | | | X | | | | | Lambda Light Chain (Total) | |
| | | | | | | | | | | | X | | | | | | LD (LDH) | |
| | | | X | | | | | | | | | | | | | | LDL-Cholesterol | |
| | | | | | | | | | | | | | | | X | | Leucocytes | |
| | | | | | | | | | | | X | | | | | | Lipase | |
| | | | X | | | | | | | | | | | | | | Lipoprotein (a) | |
| | | | | | | | | | | | | | | X | | | Lithium | |
| | | | | | | | | | | | | | | | X | | Lorazepam | |
| | | | | | | | | | | | | | | | X | | LSD | |
| | | | | | | | | | | | | | | | | | Luteinising Hormone (LH) | |
| | | | | | | | | | | | X | | | | | | Magnesium | M |
| | | | | | | | | | | | | | | | X | | MDMA | |
| | | | | | | | | | | | | | | | | | Mean Cell Haemoglobin (MCH) | |
| | | | | | | | | | | | | | | | | | Mean Cell Haemoglobin Concentration (MCHC) | |
| | | | | | | | | | | | | | | | | | Mean Cell Volume (MCV) | |
| | | | | | | | | | | | | | | | | | Mean Platelet Volume (MPV) | |
| | | | | | | | | | | | | | | | | | Metanephrine | |
| | | | | | | | | | | | | | | | X | | Methadone | |
| | | | | | | | | | | | | | | | | | Methaemoglobin (MetHb) | |
| | | | | | | | | | | | | | X | | | | Methotrexate | |
| | | | | | | | | | | | | | | | | | Monocyte Chemoattractant Protein -1 (MCP-1)* | |
| | | | | | | | | | | | | | | | | | Myoglobin | |

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

⁴ Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

| | | Ammonia / Ethanol | Anti-Mullerian Hormone (AMH) + | Anti-TSH Receptor + | Blood Gas | BNP + | Cardiac | Cardiac Plus | Cerebrospinal Fluid + | Coagulation | CO-Oximetry + | CYFRA 21-1 + | Cytokines + | ESR + | General Clinical Chemistry | HbA1c | Haematology | Human Urine | Immunoassay | |
|---|----------------------------------|-----------------------------------|--------------------------------|---------------------|-----------|-------|---------|--------------|-----------------------|-------------|---------------|--------------|-------------|-------|----------------------------|-------|-------------|-------------|-------------|---|
| N | NEFA | | | | | | | | | | | | | | X | | | | | |
| | Nitrite | | | | | | | | | | | | | | | | | | | |
| | Non-HDL Cholesterol | | | | | | | | | | | | | | X | | | | | |
| | Norepinephrine | | | | | | | | | | | | | | | | | X | | |
| | Normetanephrine | | | | | | | | | | | | | | | | | X | | |
| | Norpropoxyphene | | | | | | | | | | | | | | | | | | | |
| | Nortriptyline | | | | | | | | | | | | | | | | | | | |
| | NTproBNP | | | | | | | X | | | | | | | | | | | | |
| O | Oestradiol | | | | | | | | | | | | | | | | | | X | |
| | Osmolality | | | | | | | | | | | | | | X | | | X | | |
| | Osteocalcin | | | | | | | | | | | | | | | | | | | |
| | Oxalate | | | | | | | | | | | | | | | | | X | | |
| | Oxazepam | | | | | | | | | | | | | | | | | | | |
| | Oxygen Content (O2CT) | | | | | | | | | | X | | | | | | | | | |
| | Oxygen Saturation (sO2 / Vol O2) | | | | | | | | | | X | | | | | | | | | |
| | Oxyhaemoglobin (O2Hb / HbO2) | | | | | | | | | | X | | | | | | | | | |
| P | P24* | | | | | | | | | | | | | | | | | | | |
| | PAPP-A | | | | | | | | | | | | | | | | | | | |
| | Paracetamol (Acetaminophen) | | | | | | | | | | | | | | | | | | X | |
| | pCO ₂ | | | | X | | | | | | | | | | | | | | | |
| | pH | | | | X | | | | | | | | | | | | | | | |
| | Phencyclidine | | | | | | | | | | | | | | | | | | | |
| | Phenobarbital | | | | | | | | | | | | | | | | | | X | |
| | Phenytoin | | | | | | | | | | | | | | | | | | X | |
| | Phosphate (Inorganic) | | | | | | | | | | | | | | X | | | X | | |
| | Plasma Renin Activity | | | | | | | | | | | | | | | | | | | |
| | Plasminogen | | | | | | | | | X | | | | | | | | | | |
| | Plateletcrit (PCT) | | | | | | | | | | | | | | | | | X | | |
| | Platelets (PLT) | | | | | | | | | | | | | | | | | X | | |
| | pO ₂ | | | | X | | | | | | | | | | | | | | | |
| | Potassium | | | | X | | | | | | | | | | X | | | X | | |
| | Prealbumin (Transthyretin) | | | | | | | | | | | | | | | | | | | |
| | Primidone | | | | | | | | | | | | | | | | | | | |
| | Procalcitonin | | | | | | | | | | | | | | | | | | | |
| | Progesterone | | | | | | | | | | | | | | | | | | X | |
| | Prolactin | | | | | | | | | | | | | | | | | | X | |
| | Protein (Total) | | | | | | | | X | | | | | | X | | | X | | |
| | Protein C | | | | | | | | | | X | | | | | | | | | |
| | Protein S | | | | | | | | | | X | | | | | | | | | |
| | PSA (Free) | | | | | | | | | | | | | | | | | | X | |
| | PSA (Total) | | | | | | | | | | | | | | X | | | | X | |
| | PT (Including INR) | | | | | | | | | X | | | | | | | | | | |
| | PTH | | | | | | | | | | | | | | | | | | | X |
| | R | Red Blood Cell Count (RBC) | | | | | | | | | | | | | | | | X | | |
| | | Red Cell Distribution Width (RDW) | | | | | | | | | | | | | | | | X | | |
| | | Renin (Direct Concentration) | | | | | | | | | | | | | | | | | | |
| | | Retinol Binding Protein | | | | | | | | | | | | | | | | | | |
| | | Rheumatoid Factor | | | | | | | | | | | | | | | | | | |
| S | Salicylic Acid | | | | | | | | | | | | | | | | | | X | |
| | Secobarbital | | | | | | | | | | | | | | | | | | | |
| | SHBG | | | | | | | | | | | | | | | | | | X | |

^a Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

| Immunoassay Speciality 1 | Immunoassay Speciality 2 | Immunosuppressant + | Lipid | Maternal Screening | Microbiology (Bacterial Identification) + | Neonatal Bilirubin + | Serology (EBV) + | Serology (HIV / Hepatitis) + | Serology (Syphilis) + | Serology (ToRCH) + | Serum Indices + | Specific Proteins | Sweat Testing + | Therapeutic Drug | Urinalysis | Urine Toxicology + | | |
|--------------------------|--------------------------|---------------------|-------|--------------------|---|----------------------|------------------|------------------------------|-----------------------|--------------------|-----------------|-------------------|-----------------|------------------|------------|--------------------|-----------------------------------|---|
| | | | | | | | | | | | | | | | X | | NEFA | N |
| | | | | | | | | | | | | | | | | | Nitrite | |
| | | | | | | | | | | | | | | | | | Non-HDL Cholesterol | |
| | | | | | | | | | | | | | | | | | Norepinephrine | |
| | | | | | | | | | | | | | | | | | Normetanephrine | |
| | | | | | | | | | | | | | | | | X | Norpropoxyphene | |
| | | | | | | | | | | | | | | | | X | Nortriptyline | |
| | | | | | | | | | | | | | | | | | NTproBNP | |
| | | | | | | | | | | | | | | | | | Oestradiol | O |
| X | | | | | | | | | | | | | | | | | Osmolality | |
| | | | | | | | | | | | | | | | | | Osteocalcin | |
| | | | | | | | | | | | | | | | | | Oxalate | |
| | | | | | | | | | | | | | | | | X | Oxazepam | |
| | | | | | | | | | | | | | | | | | Oxygen Content (O2CT) | |
| | | | | | | | | | | | | | | | | | Oxygen Saturation (sO2 / Vol O2) | |
| | | | | | | | | | | | | | | | | | Oxyhaemoglobin (O2Hb / HbO2) | |
| | | | | | | | | X | | | | | | | | | P24* | P |
| | | | | X | | | | | | | | | | | | | PAPP-A | |
| | | | | | | | | | | | | | | X | | | Paracetamol (Acetaminophen) | |
| | | | | | | | | | | | | | | | | | pCO ₂ | |
| | | | | | | | | | | | | | | | X | | pH | |
| | | | | | | | | | | | | | | | | X | Phencyclidine | |
| | | | | | | | | | | | | | | X | | X | Phenobarbital | |
| | | | | | | | | | | | | | | X | | | Phenytoin | |
| | X | | | | | | | | | | X | | | | | | Phosphate (Inorganic) | |
| | | | | | | | | | | | | | | | | | Plasma Renin Activity | |
| | | | | | | | | | | | | | | | | | Plasminogen | |
| | | | | | | | | | | | | | | | | | Plateletcrit (PCT) | |
| | | | | | | | | | | | | | | | | | Platelets (PLT) | |
| | | | | | | | | | | | | | | | | | pO ₂ | |
| | | | | | | | | | | | | X | | | | | Potassium | |
| | | | | | | | | | | | | X | | | | | Prealbumin (Transthyretin) | |
| X | X | | | | | | | | | | | | | X | | | Primidone | |
| | | | | | | | | | | | | | | | | | Procalcitonin | |
| | | | | | | | | | | | | | | | | | Progesterone | |
| | | | | | | | | | | | | | | | | | Prolactin | |
| | | | | | | | | | | | X | | | | | X | Protein (Total) | |
| | | | | | | | | | | | | | | | | | Protein C | |
| | | | | | | | | | | | | | | | | | Protein S | |
| | | | | | | | | | | | | | | | | | PSA (Free) | |
| | | | | | | | | | | | | | | | | | PSA (Total) | |
| | | | | | | | | | | | | | | | | | PT (Including INR) | |
| X | | | | | | | | | | | | | | | | | PTH | |
| | | | | | | | | | | | | | | | | | Red Blood Cell Count (RBC) | R |
| | X | | | | | | | | | | | | | | | | Red Cell Distribution Width (RDW) | |
| | | | | | | | | | | | | X | | | | | Renin (Direct Concentration) | |
| | | | | | | | | | | | | X | | | | | Retinol Binding Protein | |
| | | | | | | | | | | | | | | | | | Rheumatoid Factor | |
| | | | | | | | | | | | | | | X | | | Salicylic Acid | |
| | | | | | | | | | | | | | | | X | | Secobarbital | S |
| | | | | | | | | | | | | | | | | | SHBG | |

⁴ Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

| | | Ammonia / Ethanol | Anti-Mullerian Hormone (AMH) + | Anti-TSH Receptor + | Blood Gas | BNP + | Cardiac | Cardiac Plus | Cerebrospinal Fluid + | Coagulation | CO-Oximetry + | CYFRA 21-1 + | Cytokines + | ESR + | General Clinical Chemistry | HbA1c | Haematology | Human Urine | Immunoassay |
|--|--|-------------------|--------------------------------|---------------------|-----------|-------|---------|--------------|-----------------------|-------------|---------------|--------------|-------------|-------|----------------------------|-------|-------------|-------------|-------------|
| S | Sirolimus | | | | | | | | | | | | | | | | | | |
| | Sodium | | | | X | | | | X | | | | | | X | | | X | |
| | Specific Gravity | | | | | | | | | | | | | | | | | | |
| | Strain Identification | | | | | | | | | | | | | | | | | | |
| | Syphilis | | | | | | | | | | | | | | | | | | |
| T | T ₃ (Free) | | | | | | | | | | | | | | X | | | | X |
| | T ₃ (Total) | | | | | | | | | | | | | | X | | | | X |
| | T ₄ (Free) | | | | | | | | | | | | | | X | | | | X |
| | T ₄ (Total) | | | | | | | | | | | | | | X | | | | X |
| | Tacrolimus | | | | | | | | | | | | | | | | | | |
| | Testosterone (Free)* | | | | | | | | | | | | | | | | | | X |
| | Testosterone (Total) | | | | | | | | | | | | | | | | | | X |
| | Theophylline | | | | | | | | | | | | | | | | | | X |
| | Thyroglobulin | | | | | | | | | | | | | | | | | | X |
| | TIBC | | | | | | | | | | | | | | X | | | | |
| | Tobramycin | | | | | | | | | | | | | | | | | | |
| | Total hCG | | | | | | | | | | | | | | | | | | |
| | Transferrin | | | | | | | | | | | | | | | | | | |
| | Triglycerides | | | | | | | | | | | | | | | X | | | |
| | Troponin I | | | | | | | X | X | | | | | | | | | | |
| | Troponin T | | | | | | | X | X | | | | | | | | | | |
| | TSH | | | | | | | | | | | | | | | X | | | X |
| TT | | | | | | | | | X | | | | | | | | | | |
| Tumour Necrosis Factor alpha (TNF- α)* | | | | | | | | | | | | X | | | | | | | |
| U | UIBC | | | | | | | | | | | | | | X | | | | |
| | Unconjugated Oestriol | | | | | | | | | | | | | | | | | | |
| | Urea | | | | | | | | | | | | | | X | | X | | |
| | Uric Acid | | | | | | | | | | | | | | X | | X | | |
| | Urobilinogen | | | | | | | | | | | | | | | | | | |
| V | Valproic Acid | | | | | | | | | | | | | | | | | | X |
| | Vancomycin | | | | | | | | | | | | | | | | | | X |
| | Vascular Endothelial Growth Factor (VEGF)* | | | | | | | | | | | | X | | | | | | |
| | Vitamin B12 | | | | | | | | | | | | | | | | | | X |
| | VMA | | | | | | | | | | | | | | | | X | | |
| W | Total White Blood Cell Count (WBC) | | | | | | | | | | | | | | | X | | | |
| Z | Zinc | | | | | | | | | | | | | X | | | | | |

^a Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

| Immunoassay Speciality 1 | Immunoassay Speciality 2 | Immunosuppressant + | Lipid | Maternal Screening | Microbiology (Bacterial Identification) + | Neonatal Bilirubin + | Serology (EBV) + | Serology (HIV / Hepatitis) + | Serology (Syphilis) + | Serology (ToRCH) + | Serum Indices + | Specific Proteins | Sweat Testing + | Therapeutic Drug | Urinalysis | Urine Toxicology + | | |
|--------------------------|--------------------------|---------------------|-------|--------------------|---|----------------------|------------------|------------------------------|-----------------------|--------------------|-----------------|-------------------|-----------------|------------------|------------|--------------------|--|---|
| | | X | | | | | | | | | X | | | | | | Sirolimus | S |
| | | | | | | | | | | | X | | | | | | Sodium | S |
| | | | | | | | | | | | | | | | X | | Specific Gravity | S |
| | | | | | X | | | | | | | | | | | | Strain Identification | S |
| | | | | | | | | | X | | | | | | | | Syphilis | T |
| | | | | | | | | | | | | | | | | | T ₃ (Free) | T |
| | | | | | | | | | | | | | | | | | T ₃ (Total) | T |
| | | | | | | | | | | | | | | | | | T ₄ (Free) | T |
| | | | | | | | | | | | | | | | | | T ₄ (Total) | T |
| | | X | | | | | | | | | | | | | | | Tacrolimus | T |
| | | | | | | | | | | | | | | | | | Testosterone (Free)* | T |
| | | | | | | | | | | | | | | | | | Testosterone (Total) | T |
| | | | | | | | | | | | | | | X | | | Theophylline | T |
| | | | | | | | | | | | | | | | | | Thyroglobulin | T |
| | | | | | | | | | | | | | | | | | TIBC | T |
| | | | | | | | | | | | | | | | X | | Tobramycin | T |
| | | | | X | | | | | | | | | | | | | Total hCG | T |
| | | | | | | | | | | | | X | | | | | Transferrin | T |
| | | X | | | | | | | | | X | | | | | | Triglycerides | T |
| | | | | | | | | | | | | | | | | | Troponin I | T |
| | | | | | | | | | | | | | | | | | Troponin T | T |
| | | | | | | | | | | | | | | | | | TSH | T |
| | | | | | | | | | | | | | | | | | TT | T |
| | | | | | | | | | | | | | | | | | Tumour Necrosis Factor alpha (TNF-α)* | T |
| | | | | | | | | | | | | | | | | | UIBC | U |
| | | | | X | | | | | | | | | | | | | Unconjugated Oestriol | U |
| | | | | | | | | | | | X | | | | | | Urea | U |
| | | | | | | | | | | | X | | | | | | Uric Acid | U |
| | | | | | | | | | | | | | | | | X | Urobilinogen | U |
| | | | | | | | | | | | | | | X | | | Valproic Acid | V |
| | | | | | | | | | | | | | | X | | | Vancomycin | V |
| | | | | | | | | | | | | | | | | | Vascular Endothelial Growth Factor (VEGF)* | V |
| | | | | | | | | | | | | | | | | | Vitamin B12 | V |
| | | | | | | | | | | | | | | | | | VMA | V |
| | | | | | | | | | | | | | | | | | Total White Blood Cell Count (WBC) | W |
| | | | | | | | | | | | | | | | | | Zinc | Z |

⁴ Pilot status only in certain programmes. Please check pages 42-46 for more information.

RANDOX QC PORTFOLIO

Our expertise in Quality Control have led to us creating market leading products that are tried and trusted by laboratory professionals. Our product portfolio offers high quality diagnostic solutions which offer reliable and rapid diagnosis and we believe that by providing laboratories with these tools, we can improve health worldwide.



ACUSERA - True third party controls offering complete test menu consolidation

- ▶ Uniquely combining more than 100 analytes conveniently in a single control, laboratories can significantly reduce costs and consolidate without compromising on quality. As true third party controls, unbiased performance assessment with any instrument or method is guaranteed.



ACUSERA 24•7 - Online QC software with real-time peer group statistics

- ▶ Designed for use with the Acusera range of third party controls, the Acusera 24•7 software will help you monitor and interpret your QC data. Access to an impressive range of features, including interactive charts, the automatic calculation of Measurement Uncertainty & Sigma Metrics and live peer group data generated from our extensive database of laboratory participants, ensures Acusera 24•7 is the most comprehensive package available.



MOLECULAR - IQC & EQA solutions for infectious disease testing

- ▶ Our complete quality control solutions for molecular infectious disease testing comprise hundreds of characterised viral, bacterial and fungal targets. Covering a wide range of transplant associated diseases, respiratory infections, blood borne viruses, sexually transmitted infections and more, our Molecular IQC and EQA range covers the full laboratory portfolio. Both our product offering are manufactured using only the highest quality material and the availability of whole pathogen samples ensures the performance of the patient sample is mimicked throughout.

Contact us for more information on any of our products and services:

HEADQUARTERS

Randox Laboratories Ltd, 55 Diamond Road, Crumlin, County Antrim, BT29 4QY, United Kingdom

☎ +44 (0) 28 9445 4399 ✉ marketing@randox.com 🌐 randox.com

INTERNATIONAL OFFICES



AUSTRALIA

Randox (Australia) Pty Ltd.
Tel: +61 (0) 2 9615 4640



BRAZIL

Randox Brasil Ltda.
Tel: +55 11 5181-2024



CHINA

Randox Laboratories Ltd.
Tel: +86 021 6288 6240



CZECH REPUBLIC

Randox Laboratories S.R.O.
Tel: +420 2 1115 1661



FRANCE

Laboratoires Randox
Tel: +33 (0) 130 18 96 80



GERMANY

Randox Laboratories GmbH
Tel: +49 (0) 215 1937 0611



HONG KONG

Randox Laboratories Hong Kong Limited
Tel: +852 3595 0515



ITALY

Randox Laboratories Ltd.
Tel: +39 06 9896 8954



INDIA

Randox Laboratories India Pvt Ltd.
Tel: +91 80 2802 5000



POLAND

Randox Laboratories Polska Sp. z o.o.
Tel: +48 22 862 1080



PORTUGAL

Irandox Laboratorios Quimica Analitica Ltda
Tel: +351 22 589 8320



PUERTO RICO

Clinical Diagnostics of Puerto Rico, LLC
Tel: +1 787 701 7000



REPUBLIC OF IRELAND

Randox Teoranta
Tel: +353 7495 22600



SLOVAKIA

Randox S.R.O.
Tel: +421 2 6381 3324



SOUTH AFRICA

Randox Laboratories SA (Pty) Ltd.
Tel: +27 (0) 11 312 3590



SOUTH KOREA

Randox Korea
Tel: +82 (0) 31 478 3121



SPAIN

Laboratorios Randox S.L.
Tel: +34 93 475 09 64



SWITZERLAND

Randox Laboratories Ltd. (Switzerland)
Tel: +41 41 810 48 89



UAE

Randox Medical Equipments Trading LLC
Tel: +971 55 474 9075



USA

Randox Laboratories-US, Ltd.
Tel: +1 304 728 2890



VIETNAM

Randox Laboratories Ltd. Vietnam
Tel: +84 (0) 8 3911 0904

For technical support contact: mail@riqas.com

Whilst every attempt is made to ensure that information is accurate and up-to-date, some information is subject to change.

Please contact marketing@randox.com for current details.

